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Clostridium difficile is the most prevalent single cause of nosocomial 
infection in the United States. A major risk factor for Clostridium difficile infection 
(CDI) is exposure to antibiotics. Antibiotics increase susceptibility to CDI by 
altering the gut microbial community, enabling increased germination of spores 
and growth of vegetative cells.  Despite being a major risk factor, antibiotics are 
currently the principal treatment for the disease. The cycle of antibiotic usage 
associated with CDI is likely why twenty-five percent of patients with CDI fail 
antibiotic therapy and experience recurrent disease. An alternative treatment, 
such as limiting colonization with toxigenic C. difficile by prior colonization of 
susceptible patients with non-toxigenic strains of C. difficile has been utilized with 
some success in clinical trials. However the mechanisms underlying how prior 
colonization with C. difficile limits disease are unknown.  The work described in 
this dissertation sought to determine the relative contribution of host and bacterial 
factors in mediating protection from CDI. Using a murine model of C. difficile, I 
present evidence in support of a novel paradigm of colonization resistance. In 
this model depletion of the amino acid glycine by prior colonization with one 
strain of C. difficile protects from lethal CDI by limiting germination of the 
incoming strain. Additionally, I show that unlike other gastrointestinal infections, 
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adaptive immunity is not required for clearance of C. difficile, rather clearance is 
associated the presence of two members of the Lachnospiraceae family in the 
indigenous untreated microbial community.  Finally, I describe the use of human 
intestinal organoids to study CDI in the context of a complex human epithelium.  
Together these results underscore the importance of bacterial interactions in 
providing protection from colonization while attributes of the host and pathogen 
may alter the pathogenesis of the infection. These results are important because 
they provide new insights into this important nosocomial infection. Furthermore 
the role of glycine in providing colonization resistance provides a novel target for 











Discovery and Epidemiology of Clostridium difficile  
 
Clostridium difficile is a Gram-positive, spore-forming, anaerobic, bacillus. 
Originally named Bacillus difficilis for its morphology and its difficulty to cultivate, 
the species was first isolated in 1935 by Hall and O’Toole during a study 
characterizing changes in the maturing infant fecal bacterial community (1). 
Ominously, while the infants from whom this bacterium was isolated were 
seemingly healthy, the authors reported that spent culture media from this new 
species caused disease and even death in rabbits and guinea pigs. Almost forty 
years later, C. difficile emerged as a clinically important pathogen when it was 
linked to the development of pseudomembranous colitis in patients receiving 
antibiotics (2-4). We now know that colonization with C. difficile can result in 
asymptomatic carriage, mild diarrhea, pseudomembranous colitis, or even death. 
Currently, C. difficile infection (CDI) is the most prevalent hospital-acquired 
infection in the US, resulting in nearly 500,000 cases and 15,000 deaths a year 
(5).  
CDI is a multistep infection (figure 1.1). First, alterations to the 
membership and/or function of gut microbiota leave the host susceptible to 
colonization (6-8). Colonization occurs via the fecal-oral route and can be 
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contracted from either infected individuals or from contaminated environmental 
sources. The metabolically dormant and ethanol-resistant spore is believed to be 
the primary transmissive form of the bacterium (9). Following ingestion, signals in 
the intestine such as glycine and the bile acid taurocholate induce germination of 
the spore into the metabolically active vegetative cell, which replicates in the 
large intestine (10-12). Finally, additional signals such as depletion of nutrients 






Figure 1.1: Clostridium difficile infection is a multistep disease 
The intact gut microbiota protects from colonization with C. difficile. However 
following a perturbation such as antibiotic therapy, the altered community can be 
susceptible to colonization. C. difficile is believed to persist in the environment as 
a metabolically dormant spore. Upon ingestion and exposure to the correct 
environmental cues in the gut, the spore germinates into a vegetative cell that 
requires specific nutrients to replicate. Disease is mediated by its toxins (TcdA, 
TcdB and CDT), which are expressed during the later stage of growth. 
Sporulation is often observed concomitantly with toxin production in the later 
growth phase, completing the cycle.   
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C. difficile is a promiscuous pathogen, in that it can colonize and cause 
disease in many different animals including cats, dogs, pigs, horses and birds 
(14-17). While some data suggests transmission of C. difficile can occur between 
animals and humans, it remains to be proven if C. difficile is a truly a zoonotic 
disease or if colonization of animals and humans with the same strains merely 
points to high levels of environmental C. difficile (18, 19).   
Major risk factors for acquiring CDI include: hospitalization, antibiotic 
exposure, and age over sixty-five years (20, 21). While clindamycin was first 
associated with the susceptibility to CDI, almost all classes of antibiotics have 
since been demonstrated to increase susceptibility in either humans or animal 
models of infection (22-25).  Some classes of antibiotics impose a greater risk of 
developing CDI; limiting the use of antibiotics known to be associated with the 
development of CDI can reduce the incidence of the disease (24, 26, 27). Other 
factors that are associated with development of CDI include comorbidities such 
as inflammatory bowel disease, solid organ transplant and immune suppression 
(28-30). Proton pump inhibitors have also been proposed to increase risk for 
CDI, however the data on this association are less conclusive (31, 32).  In 
addition to primary infection, recurrent infection is increasingly a problem with 
approximately one in five patients experiencing recurrent CDI (33). Patients that 
experience a first recurrence are increasingly likely to experience additional 
bouts of recurrent CDI (34). Although it is unknown why certain patients 
experience recurrence while others do not, failure of the microbiota to recover 
following antibiotics and or decreased humoral response to the toxins might play 
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a role (30, 35, 36). Currently the IDSA recommended therapy for treatment of 
both primary and recurrent CDI is the antibiotic vancomycin (37).  Recently 
studies reporting a greater than 85% success rate for treatment of recurrent CDI 
with fecal microbial transplants has resulted in increased use of this therapy (38).  
In the early 2000’s the epidemiology of CDI changed, with a sharp 
increase in the incidence and severity of infection. This change is at least 
partially attributed to the emergence of a clade of C. difficile termed ribotype 027 
(39). Ribotype 027’s emerged in North America and went on to spread worldwide 
over the first decade of this century (40).  These new strains of C. difficile were 
associated with more severe disease as well as increased relapse following 
treatment (41).  Other clades of C. difficile such as the 078 have now also been 
associated with these phenotypes. Another major change in the epidemiology of 
CDI is the increased incidence of the disease in populations that were previously 
considered low-risk for infection, such as patients with no recent healthcare 
exposure (42, 43). It is unclear what is driving the worrying trend of increased 
community-associated CDI.  
Currently, the incidence of CDI seems to have leveled, potentially due to 
changes in hospital policy such as better antibiotic stewardship (44). 
Interestingly, antibiotics seem to have been a strong influence on not only in 
terms of increasing susceptibility of the host to infection but also in terms of 
selection for the increase prevalence of strains that carry resistance to the same 
class of antibiotic.  Nevertheless, CDI remains a serious health threat in the 





C. difficile is a genetically diverse species. Even between sub strains of C. 
difficile like the common laboratory strains 630 and 630Δerm there is much 
phenotypic variation (45). This diversity has led to controversy within the field 
when attempting to delineate the roles of the toxins as well as various other 
genes in the pathogenesis of infection (46-48). Additionally, relative to the 
commonly studied Gram-negative pathogens, the laborious process of 
generating clean mutations in both lab and clinical isolates has hampered 
determination of the specific roles of C. difficile genes in pathogenesis.  
C. difficile causes disease via production of toxins. To date, all reported 
isolates carry up to three toxins (TcdA, TcdB and CDT).  Strains that do not 
encode at least one of the three toxins do not cause disease (46, 49, 50). The 
primary virulence factors are the toxins carried within a 19.6kb region of the 
chromosome called the pathogenicity locus (Paloc) (51). Within the Paloc, the 
genes tcdA and tcdB encode the proteins toxin A (TcdA) and toxin B (TcdB), 
respectively.  In addition to the toxins, the Paloc encodes an alternative sigma 
factor, tcdR, which positively regulates toxin production, as well as tcdC, a 
negative regulator of transcription (52-54). The final gene encoded in this locus is 
tcdE.  TcdE is a putative phage-like holin, which is thought to facilitate secretion 
of the toxins (55).  The Paloc genes can each be transcribed from their own 
promoters in addition to being transcribed as one polycistronic transcript (56, 57).  
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TcdA may be produced in higher quantities than TcdB, as transcripts of tcdA 
have been observed to be twice as abundant as tcdB transcript (57, 58).  
Regulation of the Paloc is tied to many aspects of C. difficile metabolism.  
In vitro studies show that the master transcription factor CodY suppresses toxin 
production in the presence of high intracellular levels of branched chain amino 
acids (59).  The amino acids cysteine, proline, as well as other easily 
metabolized carbon sources such as glucose also suppress toxin production (60-
63).  Conversely, toxin production is increased in stationary phase cultures 
suggesting that nutrient limitation also regulates the toxins.  
Recent work by Jenior et al. showed that, in the context of different 
bacterial communities and thus varied metabolite milieus, the same strain of C. 
difficile expresses different levels of toxin, as measured by a cell cytotoxicity 
assay (64). This hints at a possible means by which individuals colonized with 
the same strain might experience varying severity of disease due to differences 
in the metabolites available to C. difficile. In addition, some strains of C. difficile 
regulate toxin production in response to their own population density through 
accessory gene regulator (Agr) mediated quorum signaling (65, 66). Integration 
of multiple environmental signals into regulation of its major virulence factors is 
fitting for a bacterium that relies so heavily on the status of the surrounding 
microbial community to carry out its life cycle.  Furthermore, it suggests that the 
toxins many serve as a means for the bacterium to either acquire new nutrients 
sources or perhaps as an exit plan, as sporulation is thought to be timed with 
production of toxins.  
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The toxins TcdA and TcdB are large multi-domain proteins of 
approximately 308 and 270 KDa respectively.  The proteins share a similar 
overall structure and within certain strains can have as much as 66% similarity 
(67). The region of most difference is the C-terminal domain, consisting of 
multiple olligopeptide repeats. This region is thought to mediate binding of the 
toxin to its cellular receptors. The currently identified receptors for TcdA are 
carbohydrates and the glycoprotein 96 (gp96) (68-70).  However in vitro studies 
show that the C-terminal section of TcdA is not required for entry into the cell (71, 
72). This suggests that another portion of the toxin is able to bind to mediate cell 
entry. Until recently the receptors for TcdB were unknown.  In the last few years, 
three putative receptors have been identified: Wnt receptor frizzled family 
proteins (specifically FZD 1, 2 and 7), Chondroitin sulfate proteoglycan 4 
(CSPG4), and Poliovirus receptor-like 3 (PLV3) (73-75).  There is still 
controversy as to which of the three currently identified receptors actually 
contribute to disease in humans  as CSPG4 is not actually expressed on the 
human colon epithelium (76). Determining the true receptors for the toxins will be 
crucial to understanding the pathogenesis of this infection. For example, whereas 
other bacterial causes of pseudomembranous colitis result in disease of the small 
bowel, a defining feature of CDI is that it is primarily a disease of the large bowel.  
At least one of the receptors, PLV3, is primarily expressed in the colon and not in 
the small intestine, which might explain the tissue tropism of CDI.  
Following attachment, entry of the toxins into the cell was believed to be 
through clathrin-mediated endocytosis. While this is true of TcdB, TcdA can enter 
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the cell via both clathrin dependent and independent mechanisms (77). It is 
tempting to speculate that the different routes of entry might modulate the effect 
of the toxin on their cellular targets. Following endocytosis, the pH of the vesicle 
decreases, causing the hydrophobic translocation domain to insert into the 
membrane of the vesicle (78). Then the toxin’s cysteine protease, with the aid of 
a host lipid inositol hexakisphosphate (InsP6) and zinc, cleaves off the N terminal 
enzymatic portion of the toxin (79-81). 
The N-terminal domain is a glycosyltransferase.  Once this domain is 
released from the holotoxin, it traffics to the apical cell membrane where it acts 
on its cellular targets: host GTPases such as Rho A, B, C, G Rac1-3 and Cd42 
(82). Some strains of C. difficile have variations of TcdA and TcdB, that interact 
with slightly different cellular targets (83-86). Both TcdA and TcdB inactivate host 
GTPases via the transfer a glucose moiety onto either Thr37 or Thr35 of the 
GTPase, blocking its interaction with its effectors (87, 88). Rho family GTPases 
are integral to many cellular processes, such as regulating cytoskeletal structure 
and cell-cell contact; thus, inactivation results in many downstream effects (89).  
Broadly, glycosyltransferase-mediated inactivation of Rho family proteins can 
cause cytopathic effects, such as cell rounding, and death. While TcdA requires 
the glycoslytrasferase domain to cause cell death, at high concentrations TcdB 
can cause a necrotic cell death independent of its enzymatic activity (90, 91).  
Some strains of C. difficile, most notably the ribotype 027 and 078 clades, 
express a third toxin called C. difficile transferase (CDT). This toxin is encoded in 
a 6.2 kb region of the chromosome termed the CdtLoc that is separate from the 
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Paloc. This locus is not carried by all strains of C. difficile; some strains 
completely lack the locus while others have cdtR but only retain a cdtAB 
pseudogene (92). The CdtLoc has three genes, cdtR, ctdA, and cdtB.   CdtR 
encodes the transcriptional regulator of the locus, which additionally regulates 
the expression of TcdA and TcdB (93, 94).   CDT is often called C. difficile binary 
toxin because it requires two components, CDTa and CDTb, to intoxicate cells.  
CDTb, the binding domain, is similar to Clostridium perfringens iota toxin; like iota 
toxin, CDTb utilizes lipolysis-stimulated lipoprotein cellular receptor for binding 
and internalization of CDT into host cells (95, 96).  CDTa, the enzymatic portion 
of the toxin, binds a heptamer of CDTb. Following endocytosis and release into 
the host cell, CDTa mono-ADP-ribosylates globular actin(97). Ribosylation of 
actin disrupts microtubule structure, resulting in fingerlike projections from 
epithelial cells in vitro. To date the signals, that induce expression of CDT have 
yet to be fully characterized.  While CDT is not required for virulence as strains 
that carry only CDT are avirulent in animal models, CDT can enhance virulence 
(98, 99). Another proposed role of CDT is enhancing colonization via increased 
adherence to the epithelium (100, 101).  It should be noted that in animal models, 
no defect in initial colonization has been observed for strains that lack the binary 
toxin. In fact, the strains that lack all toxins colonize to the same level as strains 
with all three (7). This paradox begs the question of what if any role the toxins 
play in facilitating colonization. One study suggested that a 027 isolate, strain 
R20291, was able to persistently colonize a mouse while a historical strain that 
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lacked CDT was cleared (102). The role of the toxins in persistent colonization of 
the gut remains to be elucidated.  
 
The Role of the Microbiome in CDI   
The bacterial community that inhabits our gut plays a crucial role in the 
development of host physiology and health (103-105). In addition, the microbiota 
also provides protection from invading pathogens, an attribute termed 
colonization resistance (106, 107). In retrospect, the vital link between our 
resident gut bacteria and C. difficile was tantalizingly plain from its first discovery.  
C. difficile was recovered from the feces of infants, which we now know have 
relatively low diversity microbial communities that in some ways resemble the 
antibiotic-treated gut of an adult (108, 109).  Understanding how the microbiota 
mediates colonization resistance is an active field of research. Our current grasp 
of the microbiota-mediated mechanisms that influence C. difficile colonization 
can be viewed through the framework of factors that influence the life cycle of C. 
difficile (figure 1.2).  
The first step of C. difficile colonization following ingestion of a spore is 
germination within the intestine (110). Bile acids are key signals for germination 
(110, 111).  Bile acid metabolism represents integration of both host and 
bacterial metabolism (112) . The primary bile acids chenodeoxycholate, cholate 
and their conjugated derivatives are synthesized in the liver and secreted into the 
small intestine. Most primary bile acids are reabsorbed by the terminal ileum, 
however residual primary bile acids are converted into secondary bile acids by 
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the gut microbiota (113). As a result, the large bowel typically has low levels of 
primary bile acids. In a conventional mouse, small intestinal content supports 
germination of C. difficile spores and outgrowth, while content from the cecum 
does not (114, 115).  However, following antibiotic exposure, the level of the 
primary bile acids that facilitate germination are increased in the large bowel and 
feces, wherease levels of the secondary bile acids that inhibit outgrowth of 
vegetative cells are decreased (10, 11, 116, 117). Thus the pool of bile acids in 
the gut influences both the efficiency of germination as well as growth of the 
vegetative cell, ultimately impacting colonization. Treatment of a susceptible 
mouse with a single bacterium capable of converting primary bile acids to 
secondary bile acids, namely Clostridium scindens, is sufficient to partially 
restore colonization resistance (118, 119).  However it is unclear if this 
phenotype occurs purely through modulation of the bile acid pool or if C. 
scindens provides protection via other means as well.  
Following germination, the next requirement for colonization is the ability 
of the vegetative cell to find a suitable niche to propagate itself. As defined by 
Hutchison, an organism’s niche includes all n-dimensional space that is defined 
by the resources required by an organism, such as the nutrients it  utilizes to 
grow and replicate as well as the physical space it occupies (120).  Rolf Freter 
applied the concept of an ecological niche as defined by nutrient availability to 
the microorganisms that inhabit the gut when he proposed the nutrient niche 
hypothesis, which posits that the composition of the gut microbiota is defined by 
interspecific competition for growth substrates (121). A correlate of this 
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hypothesis is that the colonization resistance is mediated by utilization of all 
available substrates by members of the microbiota. Thus, as the diversity of a 
community decreases, so should the level of colonization resistance. While a 
correlation between decreased diversity and increased susceptibility to CDI has 
frequently been remarked upon in the literature, diversity in and of itself is not 
likely to be responsible for providing colonization resistance (36).  As an 
example, germ-free mice, which completely lack resident microbes, have no 
colonization resistance to C. difficile (122, 123). However, pre-colonizing germ-
free mice with Bacteroides thetaiotaomicron (technically increasing diversity) 
increases levels of succinate in the gut resulting in higher levels of C. difficile 
upon challenge, thus arguably decreasing colonization resistance (124).  
Many early studies exploring colonization resistance to C. difficile focused 
on the importance of the intact gut microbiota in preventing colonization (122, 
125-128). They tested the hypothesis that intact community prevented 
colonization via utilization of the nutrients required by C. difficile. Recent studies 
have demonstrated that following administration of antibiotics there is a 
significant increase in the types of nutrients C. difficile can utilize for growth, such 
as sugar alcohols and amino acids (115, 129).  However, a limitation of these 
studies is that most fail to directly prove that the members of the microbiota that 
are decreased following antibiotics actually limit colonization of C. difficile via 
competition for those specific nutrients. Thus while direct evidence in support of 
the nutrient niche hypothesis has been demonstrated with respect to other 
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bacteria such as Escherichia coli, it has yet to be fully supported with regard to C. 
difficile (130).   
In addition to the general nutritional requirements for growth, a niche is 
also defined by the abiotic requirements such as the features that define the 
physical habitat of the organism. Beyond nutrients, the remaining aspects of C. 
difficile’s niche space have been poorly defined. Recent work has sought to 
define localization of C. difficile in the intestine, however the data are conflicting. 
Some studies suggest that it colonizes close to the mucosa or even the crypts, 
while others suggest that it mainly resides in the outer mucus layer (131, 132).  
The question of where an organism lives seems mundane,, but it can be a crucial 
factor in explaining colonization resistance. In the case of certain Bacteroides, 
two different species are both able to colonize a germ-free mouse. However, pre-
colonization with one strain precludes stable colonization with another strain of 
the same species. This phenotype was found to be associated with a specific 
locus, which enables localization of strains carrying those genes to the colonic 
crypts and thus saturation of that species’ spatial niche (133). It is tempting to 
speculate that perhaps one of proteins that has been reported to facilitate C. 
difficile adhesion to the colonic epithelium, such as the surface layer protein 
(SlpA), may play a similar role (134, 135).  
In addition to limiting the replicative ability of the vegetative cell, 
colonization of C. difficile may also be limited by inhibitors produced by other 
bacteria (136). Bacteriocins are small bactericidal proteins produced by bacteria 
often to inhibit closely related species (137).  Some strains of C. difficile can 
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produce a R-type bacteriocin which when given prophylactically protects mice 
from colonization (138).  A recent report of successful treatment of recurrent CDI 
using sterile fecal microbiota transplants also hints at the potential of molecules 
produced by the resident microbiota to directly inhibit C. difficile in the absence of 
viable bacteria (139).  
Following colonization, the development of disease is ultimately 
dependent on both the activity of, and response to, C. difficile toxins.  Much of 
the what we know regarding how the toxins interact with cells has been learned 
through the use of in vitro cell culture systems using epithelial cell lines such as 
Caco2, HT29, or Vero cells. However these systems lack much of the complexity 
inherent to an in vivo infection, such as the different cell types that make up the 
gastrointestinal tract or the ability to co-culture members of the microbiota. These 
are major limitations, since many studies show that the microbiota and/or 
microbial products play an important role in modulating the activity of the toxins 
and thus the course of disease. Certain strains of Bifidobacteria and Lactobacilli 
can decrease toxin-mediated cell rounding in vitro. This finding was dependent 
on incubation of viable Bifidobacterium longum with the toxins suggesting that 
the strain is either breaking down or secreting an inhibitor of the toxins (140).  In 
a mouse model of EHEC, another toxin-mediated intestinal infection, acetate (a 
byproduct of microbial fermentation) protected mice from severe disease (141). 
Recently, potassium acetate mediated inhibition of histone deacetylase 6 was 
shown to protect from TcdA mediated inflammation (142). It would be interesting 
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to determine whether the short chain fatty acid acetate can protect from TcdA via 
a similar mechanism in vivo.  
Elucidating the mechanisms that underlie microbiota-mediated 
colonization resistance and protection from disease is a critical area of 
investigation.  Not solely because of the potential to derive novel therapeutics to 
treat CDI, but also because this knowledge will likely be necessary to combat 





Figure 1.2. Mechanisms of protection from CDI 
The mechanisms of protection from CDI can be viewed through the framework of 
the life cycle of C. difficile. Microbiota mediated protection primarily inhibits 
germination and outgrowth which impacts colonization. While host factors such 
as anti-toxin antibodies modulate disease. There are points of intersection, such 
as microbiota-derived signals that drive protective immune responses.   
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 Host Response to Infection 
The immune response to C. difficile governs the outcome of the infection. 
Toll like receptors (TLRs), which sense conserved microbial molecules, are 
critical regulators of both innate and adaptive immunity (143).  TLR signaling in 
particular determines the response to acute infection. In the absence of MyD88, 
a critical node in TLR signaling, mice are more susceptible to severe CDI (144). 
After infection of MyD88-deficient mice, impaired neutrophil recruitment resulting 
in increased mortality (145).  In addition to TLRs, signaling though the NOD like 
proteins, specifically NOD1, also facilitates neutrophil-mediated protection of 
acute infection (146).  However the role of neutrophils in protection from CDI is 
still partially unresolved.  In most models, the inability to recruit neutrophils 
results in severe disease; however, in rabbit ileal loops, inhibition of neutrophils 
protects the tissue from damage (147).  Furthermore, there is a significant 
associated between elevated levels of Il-8, the chemokine primarily involved in 
recruitment of neutrophils, and severe disease in patients (148, 149). Perhaps 
the immune context and/or timing of recruitment relative to the infection 
potentiate the protective or harmful role of neutrophil recruitment during CDI. 
Whether this is the case is yet to be resolved. In addition to neutrophils, innate 
lymphoid cells (ILC) specifically interferon gamma producing ILC1, protect from 
severe disease in a murine model (150, 151).  Recently eosinophils, a 
heretofore-neglected cell linage in terms of bacteria infections, have been linked 
to protection from CDI. Antibiotic perturbations of the microbiota decreased levels 
of the IL-17 family cytokine IL-25, leading to decreased eosinophils and 
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increased damage to the gut epithelium (152).  Interestingly, binary toxin (CDT) 
can suppress the eosinophilic response, offering a potential explanation as to 
why some strains carrying binary toxin, like the 027 clade, might be associated 
with worse outcomes (99).   
In addition to innate immunity, adaptive immunity is also critical to the 
pathogenesis of CDI. The majority of the research analyzing adaptive immunity 
and CDI has focused on the role of anti-toxin antibodies and protection from 
symptomatic disease. Early studies noted that patients who had deceased levels 
of serum IgG against TcdA were at increased risk for recurrent disease(30, 153). 
In animal models, passive immunization protects from disease (154, 155).  
Indeed, treatment of patients with monoclonal antibodies against TcdB reduces 
recurrent infections by 50% (156).  Beyond a humoral response to the toxin, the 
impact of adaptive immunity on any other aspect of the infection is currently 
understudied.  
 
Outline of the thesis 
This thesis is based on the central hypothesis that resistance against C. 
difficile disease reflects the combined effects of host immunity and 
bacteria/bacteria competition. In chapter two, I describe a mechanism by which 
pre-colonization with one strain of C. difficile limits colonization of another via 
depletion of the amino acid glycine.  While it was known that glycine enhances  
C. difficile vegetative growth in addition to being a required co-germinant, this is 
the first report of colonization resistance mediated by limitation of glycine (12, 
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157). In chapter three, the contribution of adaptive immunity to clearance of C. 
difficile is explored via restoration of adaptive immunity into immune-
compromised infected mice. These experiments demonstrate that unlike 
infections caused by other gastrointestinal pathogens, adaptive immunity is not 
required for clearance of C. difficile. In chapter four, I characterize the use of 
intestinal organoids derived from human embryonic stem cells, as a tool to study 
the effects of C. difficile toxins on a more physiologically relevant epithelium.  
Finally, in chapter five, the implications of the findings in this thesis are 
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PROTECTION FROM LEATHAL CLOSTIRIDUM DIFFICILE INFECTION  





Clostridium difficile a Gram-positive, spore-forming bacterium is the 
primary cause of infectious nosocomial diarrhea (1, 2). Susceptibility to C. difficile 
infection (CDI) results from perturbations of the gut microbial community, 
enabling increased germination of spores and outgrowth of vegetative C. difficile 
(3, 4).  Following colonization and outgrowth, vegetative C. difficile produces 
toxins. The main toxins, TcdA and TcdB, are glycosyltransferases that inactivate 
cellular GTPases (5).  Inactivation of these key cellular proteins results in 
damage of the colonic epithelium and inflammation manifesting as diarrhea and, 
in severe cases, toxic megacolon or even death.  Currently the principal 
treatment for CDI are antibiotics (6). While antibiotics kill vegetative C. difficile, 
this therapy further disrupts the gut microbiota potentially delaying community 
recovery (7). It is hypothesized that delayed recovery of the gut microbiota is at 
least partially responsible for recurrence of disease as is experienced by 25% of 
patients (2). 
Due to the high rate of recurrent infection associated with existing 
treatment for CDI, alternative approaches that spare or even restore the gut 
microbiota have been a focus of recent work. As is the case with many toxin-
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mediated diseases early studies noted that generation of a humoral immune 
response to the toxins could be sufficient to protect against disease (8, 9).  A 
recent clinical trial demonstrated that patients receiving monoclonal antibodies 
targeting the toxins, TcdA and TcdB, were 50% less likely to experience 
recurrent disease (10, 11).  Unlike antibiotics, antibody therapy prevents illness 
while likely sparing the microbial community. 
 Recently, a non-toxigenic strain of C. difficile was demonstrated to 
successfully reduce the rate of recurrent CDI by 50% (12). The prevailing 
hypothesis is that the protection provided by the non-toxigenic strain is mediated 
by competitive exclusion via consumption of a subset of required resources such 
as nutrients, limiting the ability of toxigenic C. difficile to colonize the gut (13). 
However this has never been conclusively demonstrated to be true.   Using a 
murine model of CDI, we sought to determine how pre-colonization with one 
strain of C. difficile might protect against lethal infection by another.  
From our studies we determined that in the absence of adaptive immunity, 
pre-colonization with a less virulent strain of C. difficile is sufficient to provide 
protection from infection by a lethal strain. Using gnotobiotic mice we show that 
protection is mediated by limiting colonization of the highly virulent strain.  
Furthermore, we provide evidence that exclusion is not mediated on nutrient-
based limitation of the vegetative form of the invading strain, but rather on 
depletion of the co-germinant glycine. 
 This work is important, as it is the first study to identify a mechanism 
though which pre-colonization with C difficile, a current clinical therapy, provides 
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protection from recurrent CDI. Furthermore limitation of germination associated 




Animals and housing  
Both male and female mice age five to twelve weeks were used in these 
studies.  The wild-type C57BL/6 specific-pathogen-free (SPF) mice were from a 
breeding colony originally derived from Jackson Laboratories over a decade ago.  
The Rag1-/- (B6.129S7-Rag1tm1Mom/J) SPF mice were from a breeding colony 
started with mice from Jackson Laboratories in 2013. Germfree Rag1-/- mice 
were obtained from a colony established and maintained by the University of 
Michigan germfree facility.  
Animals were housed with autoclaved cages, bedding, and water bottles. 
Mice were fed a standard irradiated chow (LabDiet 5LOD). All mice had access 
to food and water ad libitum. Cage changes were carried out in a biological 
safety cabinet.  The frequency of cage changes varied depending on the 
experiment. To prevent cross-contamination between cages, hydrogen peroxide-
based disinfectants in addition to frequent glove changes were utilized during all 
manipulation of SPF animals.  A chlorine-based disinfectant was used during 
manipulation of the germfree mice.  All mice were maintained under 12-hours of 
light and 12-hours of darkness in facilities maintained at temperature of 72° C +/- 
4 degrees.  Animal sample size was not determined by a statistical method. 
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Multiple cages of animals for each treatment were used to control for possible 
differences in the microbiota between cages. Mice were evaluated daily for signs 
of disease, those determined to be moribund were euthanized 
by CO2 asphyxiation. The University Committee on the Care and Use of Animals 
at the University of Michigan approved this study. Animal husbandry was 
performed in an AAALAC-accredited facility.  
 
Preparation of spores 
Spore stocks of C. difficile strains 630 (ATCC BAA-1382) and VPI 10463 
(ATCC 43255) were prepared as previously described by (3) with the following 
modifications, strains were grown overnight in 5mL of Columbia broth which was 
added to 40 mL of Clospore media (14).  
 
Preparation of heat killed C. difficile  
Heat-killed C. difficile strain 630 was made from an overnight culture 
grown anaerobically at 37°C in brain-heart infusion (BHI) broth supplemented 
with 0.01% cysteine. C. difficile strain 630 was	enumerated by culturing for 
colony forming units (CFU) per mL of BHI. Following enumeration, the culture 
was removed from the chamber, spun down, and the pellet was washed and re-
suspend in PBS. The solution was autoclaved at 121°C for 30 minutes at 15 PSI 
to kill the vegetative cells and inactivate any spores.  The heat-killed C. difficile 
solution was equivalent to 2.7x1010 CFU/mL. In experiments using heat-killed C. 
difficile, mice were given 109 CFU equivalents in 0.05mL.  A portion of the sample 
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was cultured on pre-reduced cycloserine-cefoxitin-fructose agar plates containing 
0.1% taurocholate  (TCCFA) to confirm that the inactivation was successful.   
 
Infections 
  In experiments using both WT and Rag1-/- SPF mice, age and sex 
matched mice were co-housed starting at three weeks of age for thirty-three days 
through antibiotic administration.  Upon infection, animals were separated into 
single genotype housing.   
All SPF mice received the antibiotic cefoperazone (cat # 0219969501, MP 
Pharmaceuticals) dissolved in Gibco distilled water at concentration of 0.5 mg/mL 
administered ad libitum as the drinking water for either 10 or 5 days.  The 
antibiotic water was changed every two days. Following completion of antibiotics, 
mice were given plain Gibco distilled water for two days before challenge with 
either spores or water (mock). C. difficile spores suspended in 50-100µL of Gibco 
distilled water were administered via oral gavage. The number of viable spores in 
each inoculum was enumerated by culturing for CFU per mL-1 on pre-reduced 
TCCFA. Over the course of the infection, mice were weighed routinely and stool 
was collected for quantitative culture.  
In our persistent colonization model, forty-one days after primary infection 
mice were given an IP of clindamycin (Sigma, C5269) in sterile saline at 
concentration of 10 mg/kg to perturb the gut microbial community as described 
previously (3, 15). The next day mice were either mock challenged with water or 
with spores of C. difficile strain VPI 10463.  In the short-term infection model, 
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mice were challenged with one strain and the following day challenged with the 
other.  In the simultaneous co-infections, mice were challenged with different 
ratios of strain 630 and strain VPI 10463 within a total amount of 104 spores.  At 
the conclusion of the experiments mice used in dual genotype experiments were 
genotyped using DNA from an ear snip using primers and cycling conditions as 




Quantitative culture from intestinal content  
Fecal pellets or colonic content were collected from each mouse into a 
pre-weighed sterile tube. Following collection, the tubes were reweighed and 
passed into an anaerobic chamber (Coy Laboratories). In the chamber, each 
sample was diluted 1 to 10 (w/v) using pre-reduced sterile PBS and serially 
diluted. 100µL of a given dilution was spread on to pre-reduced TCCFA or when 
appropriate TCCFA supplemented with either 2 or 6µg/mL of erythromycin.  
Strain 630 is erythromycin resistant; use of 2µg/mL of erythromycin in TCCFA 
plates reduced background growth from other bacteria in the sample while 
TCCFA with 6µg/mL of erythromycin enabled selection of 630 (erythromycin 
resistant) from VPI 10463 (erythromycin sensitive).  Plates were incubated at 
37°C in the anaerobic chamber and colonies were counted at 18-24 hours. 
Plates that were used to determine if mice were negative for C. difficile were held 
for 48 hours.  
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Toxin activity assay  
Intestinal content was collected from each mouse into a pre-weighted 
sterile tube and stored at -80°C.  At the start of the assay each sample was 
diluted 1:10 weight per volume using pre-reduced sterile PBS. Following dilution, 
the sample was filter sterilized through a 0.22µm filter and the activity of the 
toxins was assessed using a Vero cell rounding-based cytotoxicity assay as 
described previously (16).   
 
Histopathology evaluation   
Mouse ceca and colon tissue were saved in histopathology cassettes and 
fixed in 10% formalin, followed by storage in 70% ethanol.  McClinchey Histology 
Lab Inc. (Stockbridge, MI) prepared the tissue including embedding samples in 
paraffin, sectioning, and generation of haematoxylin and eosin stained slides. A 
board certified veterinary pathologist scored the slides blind to the experimental 
groups, using previously described criteria (15).  
 
Anti-TcdA IgG ELISA 
Blood was collected from mice via saphenous vein puncture into capillary 
blood collection tubes. Samples were spun down and serum was stored at -80°C.  
Levels of IgG specific to C. difficile TcdA were measured in serum from mice 
using a previously described ELISA protocol (17) with a few modifications.  
Briefly, 96-well EIA plates were coated with 100µl of purified C. difficile TcdA (List 
Laboratories, cat #152C) at 1µg/mL in 0.05M sodium bicarbonate buffer pH 9.6 
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overnight at 4°C. Mouse serum was diluted to 1:400 in blocking buffer and 
serially diluted 1:3.  Each sample was run in duplicate.  Negative controls 
included pre-immune sera from the mice in addition to wells that lacked serum.  
A positive control consisting of a monoclonal mouse anti-TcdA IgG antibody was 
run on each plate.  The optical density at 410 nm was recorded on a VersaMax 
plate reader (Molecular Devices, Sunnyvale CA).  The anti-Toxin A IgG titer was 
defined as the last dilution where both replicates had an OD410 greater than mean 
absorbance of all negative wells on the plate plus three times the standard 
deviation from that mean.  
 
Serum neutralizing anti-toxin antibody assay  
The serum neutralizing anti-toxin antibody assay was based on a 
previously described assay (9).  With the following modifications:  the 
concentration of purified TcdA or TcdB  (List Laboratories) that resulted in 100% 
cell rounding was determined empirically, using the toxin activity assay. Vero 
cells were seeded at a density of 105 cells/0.075mL per well onto tissue culture 
treated plates.  Four times the concentration of toxin that resulted in 100% cells 
rounding (64µg/mL for TcdA and 4µg/mL for TcdB) was incubated with serial 
dilutions of serum from mice. The serum toxin mixture was added to Vero cells 
and incubated overnight. The neutralizing titer was determined to be the last 
dilution with had less than 50% of round cells in the well.  Each sample was run 
in duplicate and the results were averaged. Toxin only wells served as negative 
controls while goat anti-TcdA and B serum served as a positive control (TechLab 
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T5015).  Sera obtained from mice prior to infection served as an additional 
negative control.  
 
Scoring of clinical signs of disease  
Mice were scored for signs of disease based on criteria previously 
described by (18). A member of the lab who had not been party to the 
experiment scored the mice before necropsy to avoid bias.  
 
Quantitative PCR  
Primers that differentiated strain VPI 10463 (IMG Genome ID: 
2512047057) from strain 630 (GenBank: AM180355.1) were designed using 
publically available genomes.  While the primers differentiated between the 
strains in pure culture they generated non-specific amplicon in the context of the 
microbiota and were only used in gnotobiotic experiments.  VPI 10463 primers:  
Forward: 5’- TTTCACATGAGCGGACAGGC -3’, Reverse: 5’-
TCCGAAGGAGGTTTCCGGTT-3’.  The expected product size is 153 nucleotides 
and the optimal annealing temperature was experimentally determined to be 
56°C.    
For quantitative PCR, DNA from fecal samples were diluted in ultrapure 
water such that such that 20 ng of DNA was added to each reaction.  Each 
sample was run in triplicate. Samples were loaded into a Light cycler 480 
multiwell plate, with FastStart Essential DNA Green master mix, 0.5µM of each 
primer. The plate was sealed with optically clear sealing tape briefly spun down 
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and run on the Roche LightCycler 96.  The following conditions were used for 
qPCR: 95°C for 10 minutes, followed by thirty cycles of 95°C for 10 seconds, 
56°C for 10 seconds, and 72°C for 10 seconds. A melt was run at the conclusion 
of the amplification.   
Genomic DNA from VPI 10463, from a culture with a known amount of 
CFU was used to generate a standard curve. Negative controls included no 
template control wells in addition to dilutions of genomic DNA from strain 630.  
  
Preparation of sterile cecal filtrate   
The sterile cecal filtrate was prepared from SPF mice that were treated for 
ten-days with cefoperazone. Uninfected mice were sacrificed two or three days 
after the completion of the antibiotics (days 0 and 1 respectively of the infection 
model). Media was also made from infected mice, following our antibiotic regime, 
two days after the completion of antibiotics mice were infected with strain 630 
and sacrificed one day later (day 1 post infection).  Following euthanasia, the 
cecum was removed and the content was squeezed into a sterile 50mL conical. 
The conical was spun at 3000 rpm at room temperature for ten minutes to 
separate the solid matter from the liquid portion.  The liquid portion of the sample 
was removed and diluted 1:2 by volume in sterile PBS (pH 7.4). The sample was 
spun again at 3000 rpm for 5 minutes at room temperature; the liquid portion was 
then filter sterilized using filters with successively smaller pore size  (from 0.8µm, 
to 0.45µm, and finally a 0.22µm filter).  Following passage through the 0.22µm 
filter, the media was frozen at -80°C until use.  The media was tested for sterility 
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by inoculating into pre-reduced BHI in the anaerobic chamber; samples that gave 
rise to turbid growth within 48 hours were discarded.  
 
Ex vivo vegetative growth  
 To determine if 24 hours of C. difficile strain 630 growth depletes the gut of the 
nutrients required for vegetative growth of strain VPI 10463, we used an ex vivo 
approach, utilizing sterile cecal filtrate from susceptible mice. Tubes of 180µL of 
day 0 cecal filtrate were thawed and allowed to equilibrate in the anaerobic 
chamber overnight. The inoculums were prepared from an overnight culture of C. 
difficile (strains 630 and VPI 10463) grown in BHI + 0.01% cysteine.  Each 
culture was back diluted 1:10 and incubated at 37°C for two hours. After two 
hours had elapsed, 500µL of the culture was spun down for four minutes in the 
anaerobic chamber using a mini-centrifuge. To prevent the introduction of 
nutrients from carry over BHI, the supernatant was removed and the tubes were 
spun for an additional minute.  Any remaining BHI was removed and the pellets 
were then suspended in 500µL of sterile anaerobic PBS. Both strains were then 
diluted 1:100 into sterile anaerobic PBS. 20µl of this 1:100 dilution was 
inoculated into the cecal filtrate. Vegetative CFU were enumerated at T=0, 24 
hours by culturing on CCFA (which lacks the germinant taurocholate). 
Additionally samples were plated on BHI + 0.01% cysteine to check for any 
contamination. After 24 hours, the samples were removed from the chamber; 
cells were pelleted by centrifugation at 2,000g for five minutes. The supernatant 
was filter sterilized using a 0.22µm 96-well filter plate and the sterile flow through 
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was passed back into the chamber to equilibrate overnight.  The following day, 
the VPI 10463 inoculum was prepared as described earlier and inoculated into 
the spent cecal filtrate. CFU were monitored by culturing sample at T=0, 6, and 
24 hours on CCFA and BHI+0.01% cysteine.  
 
Ex vivo germination assay 
To determine if 24 hours of strain 630 growth altars the ability of VPI 10463 
spores to germinate we performed an ex vivo germination assay based on a 
previously described method (19) with the following modifications. Rather than 
using complete cecal contents we used a sterile filtrate of cecal content from 
mice that were off of antibiotics for three days (day 1 cecal filtrate) or infected 
with C. difficile  strain 630 for 24 hours (630 day 1 cecal filtrate).  180µL aliquots 
of the cecal filtrate were thawed and allowed to equilibrate in the anaerobic 
chamber overnight. The next day 10uL of spores from strain VPI 10463 were 
inoculated into the media. Controls included sterile PBS (Gibco cat#10010023), 
PBS + 0.1% sodium taurocholate, and PBS + 0.1% sodium taurocholate + 
100mM glycine.  Following inoculation, samples were incubated anaerobically at 
RT for 15 minutes, after which approximately half the volume was immediately 
plated on BHI + 0.1% Taurocholate +0.01% cysteine agar and the tubes were 
passed out of the chamber and placed in a water filled heat block set at 65°C for 
20 minutes. The heating step kills off any vegetative cells. Additional controls 
included culturing the spore inoculum on BHI without taurocholate to check for 
presence of any vegetative cells in the stock as well as heating suspensions of 
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vegetative cells to confirm efficacy of heat killing.  Following the 20 minutes 
incubation, tubes were passed back into the chamber and the remaining sample 
was plated on BHI + 0.1% Taurocholate +0.01% cysteine agar.  The CFU 
recorded from the pre-heat plate represents the entire inoculum including 
remaining spores and any cells that germinated, while the post-heat plate 
represents only remaining spores.  
 
Metabolomics  
Quantification of relative in vivo metabolite concentrations was preformed by 
Metabolon (Durham, NC) as described previously(20).   
 
DNA extraction  
Genomic DNA was extracted from approximately 200-300 µl of fecal 
sample using the MoBio PowerSoil HTP 96 DNA isolation kit (formerly MoBio, 
now Qiagen) on the Eppendorf EpMotion 5075 automated pipetting system 
according to manufacturer’s instructions. 
 
Sequencing 
  The University of Michigan Microbial Systems Laboratory constructed 
amplicon libraries from extracted DNA as described previously(7).  Briefly, the V4 
region of the 16S rRNA gene was amplified using barcoded dual index primers 
as describe by Kozich et al. (21). The PCR reaction included the following: 5µl of 
4µM stock combined primer set, 0.15µl of Accuprime high-fidelity Taq with 2µl of 
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10× Accuprime PCR II buffer (Life Technologies, #12346094), 11.85µl of PCR-
grade water, and 1µl of template. The PCR cycling conditions were as follows: 
95° for 2 minutes, 30 cycles of 95°C for 20 seconds, 55°C for 15 seconds, and 
72°C for 5 minutes, and 10 minutes at 72°C. Following construction, libraries 
were normalized and pooled using the SequelPrep normalization kit (Life 
Technologies, #A10510-01).  The concentration of the pooled libraries was 
determined using the Kapa Biosystems library quantification kit 
(KapaBiosystems, #KK4854) while amplicon size was determined using the 
Agilent Bioanalyzer high-sensitivity DNA analysis kit (#5067-4626).  Amplicon 
libraries were sequenced on the Illumina MiSeq platform using the MiSeq 
Reagent 222 kit V2 (#MS-102-2003) (500 total cycles) with modifications for the 
primer set. Illumina’s protocol for library preparation was used for 2 nM libraries, 
with a final loading concentration of 4pM spiked with 10% genomic PhiX DNA for 
diversity.  The raw paired-end reads of the sequences for all samples used in this 
study can be accessed in the Sequence Read Archive under PRJNA388335. 
 
Sequence curation and analysis 
Raw sequences were curated using the mothur v.1.39.0 software package 
(22) following the Illumina MiSeq standard operating procedure. Briefly, paired 
end reads were assembled into contigs and aligned to the V4 region using the 
SLIVA 16S rRNA sequence database (release v128) (23), any sequences that 
failed to align were removed; sequences that were flagged as possible chimeras 
by UCHIME were also removed (24).  Sequences were classified with a naïve 
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Bayesian classifier (25) using the Ribosomal Database Project (RDP) and 
clustered in to Operational Taxonomic Units (OTUs) using a 97% similarity cutoff 
with the Opticlust clustering algorithm (26).   
The number of sequences in each sample was then rarefied to 9,000 sequences 
to minimize bias due to uneven sampling. Following curation in mothur, further 
data analysis and figure generation was carried out in R (v 3.3.3) using standard 
and loadable packages (27). The data and code for all analysis associated with 
this study are available at https://github.com/jlleslie/Intraspecific_Competition. 
For the purpose of distinguishing between values that were detected at the limit 
of detection versus those that were undetected, all results that were not detected 
by a given assay were plotted at an arbitrary point below the limit of detection 
(LOD).  However for statistical analysis, the value of LOD/√2 was substituted for 
undetected values.  Wilcoxon ranked sum test was used to determine significant 
differences and when appropriate, reported p-values were corrected for multiple 
comparisons using the Benjamini–Hochberg correction.  
 
Results 
Development of murine model of persistent C. difficile colonization  
The only single species bacterial preparation that has demonstrated 
efficacy in reducing recurrent CDI in humans is non-toxigenic C. difficile (12).  
However the mechanisms by which one strain of C. difficile prevents colonization 
of another are currently unknown. To begin to address this question we 
developed a model of persistent C. difficile colonization. Mice were made 
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susceptible to colonization via administration of the antibiotic cefoperazone. 
Following two days off of the antibiotic, mice were either mock challenged or 
challenged with C. difficile strain 630. Compared to mock-challenged animals, C. 
difficile infected animals displayed significant weight loss between days four to 
six post-challenge (figure 2.1A, p<0.05).  After a week, infected mice remained 
highly colonized although there was a significant reduction in the fecal colony 
forming units (CFU) of C. difficile relative to levels observed in the feces on day 
one post-infection (figure 2.1 B, p<0.01). Contemporaneous with the decrease in 
colonization, infected animals recovered body weight until they were 
indistinguishable from the mock-infected animals (figure 2.1A).  Additionally, the 
diversity of the gut microbiota increased within the first week of infection, a period 
corresponding to the recovery of weight and decrease in colonization (figure 2.1 
D, right axis). Throughout the experiment, toxin was detected in the feces of most 
of the infected mice despite a lack of outward signs of disease (figure 2.1 A and 
C). Together these data demonstrate that C. difficile strain 630 can persistently 
colonize wild type mice as a minority member of the gut microbiota (figure 2.1 D, 




Figure 2.1. Murine model of persistent C. difficile colonization  
A. Change in weight relative to day of infection for infected and mock challenged 
mice. Points represent median weight; bars are the upper and lower quartiles. 
Infected mice are colored blue while data from mock-infected animals are shown 
in tan.  Following correction for multiple comparisons, weight loss in infected 
mice was only significantly different than mock-challenged mice on days 4, 5, 
and 6 post-infection, p< 0.05.   
B. C. difficile colonization over time as determined by quantitative culture.  Day 1 
post-infection levels of C. difficile are significantly different from levels of 
colonization measured at day 10 post-infection through to day 40, p< 0.01. The 
hashed line represents the limit of detection of 100 CFU/g feces.  
C. Fecal toxin activity remains detectable throughout the experiment.  Toxin titer 
on day 33 and day 40 are significantly different from day 1 post-infection levels, 
p<0.05.  The hashed line represents the limit of detection for this assay, 2.3.  
D. Relative abundance of OTU 4 (C. difficile) over the course of the experiment 
(blue line) is plotted on the left axis while Shannon diversity of the infected mice 
over the course of the experiment is plotted on the right axis (black box plots).  
Statistical significance for all data was calculated using a Wilcoxon test with a 
Benjamin- Hochberg correction for multiple comparisons.  
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Pre-colonization with C. difficile protects mice from challenge with a highly 
virulent strain.  
To determine if a resident strain of C. difficile protects mice from challenge 
with a second strain in the context of perturbation to the gut microbiota, we 
administered a second antibiotic, clindamycin, to both the C. difficile infected and 
mock-infected mice. Intraperitoneal (IP) injection of clindamycin did not result in 
weight loss in either group of mice (figure 2.2 A) However, in the infected mice, 
levels of C. difficile strain 630 significantly increased following administration of 
clindamycin likely because the strain is resistant to the antibiotic (figure 2.2 B, p< 
0.001) (28).  
To control for possible variations in the microbiota across the cages, mice 
from 630-infected and mock-infected cages were split into two groups following 
the treatment with clindamycin. Approximately half the mice in a cage were 
challenged with 105 spores of C. difficile strain VPI 10463 while the rest of the 
mice were placed in a new cage and mock infected (figure 2.3 A). Strain VPI 
10463 expresses both TcdA and TcdB and is lethal in this model of infection (15, 
29).    
  Mice that that only received antibiotics and were not challenged with either 
strain of C. difficile (figure 2.3 B, tan dots) in addition to mice that were infected 
with strain 630 and then mock infected (figure 2.3 B, tan blue dots) were included 
as negative controls. Both groups maintained their weight throughout the 
treatments (figure 2.3B). Mice that had not been colonized with C. difficile strain 
630 and were subsequently infected with C. difficile strain VPI 10463 lost a 
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significant amount of weight and had to be euthanized (figure 2.3 B, red dots). 
Surprisingly mice persistently colonized with C. difficile strain 630 were protected 
from challenge with the lethal strain (yellow dots) (figure 2.3 B, red vs. yellow 
p<0.01). Additionally, strain 630 pre-colonized mice had significantly lower toxin 
titers than the naïve mice challenge with strain VPI 10463 (figure 2.3 C, p<0.05). 
This finding was confirmed by the histopathology, as the summary score for the 
histopathology of the colon was significantly less in the 630 colonized mice 
challenged with VPI 10463 compared to the naïve mice challenged with VPI 




Figure 2.2 Effect of clindamycin on weight and colonization levels  
A. Change in weight from the day mice were given clindamycin to the following 
day.  Mock-infected mice (or naïve animals) are a reference point. There was not 
a significant difference between the infected or mock-infected mice following 
administration of clindamycin, p > 0.05. 
B.  C. difficile colonization in infected animals one day prior to administration of 
clindamycin and one day following. Clindamycin significantly increases levels of 
C. difficile strain 630 in infected mice, p < 0.001. For the data included in each 




Figure 2.3. Mice pre-colonized with C. difficile strain 630 are protected from 
challenge with a lethal strain 
A. Schematic of experimental conditions.  Colors corresponding to treatment 
groups are carried throughout the figure.  
B. Percent of day of challenge weight at time of necropsy. Mice colonized with C. 
difficile strain 630 and challenged with the lethal strain (VPI 10463) are protected 
from weight loss where as mice that had no exposure to C. difficile strain 630 
experienced significant weight loss, p = 0.006061.  
C. Toxin titer from intestinal content as measured by Vero cell rounding assay. 
Mice colonized with C. difficile strain 630 and then challenged with C. difficile 
strain VPI 10463 have a lower toxin titer relative to naïve mice challenged with 
VPI 10463, p = 0.04581. The hashed line represents the limit of detection for this 
assay, 2.3. 
D. Histopathology scoring of the colon.  Small panels depict scores for each 
component that makes up the summary score.  VPI challenged 630 colonized vs. 
VPI challenged naive mice p-value = 0.008376. 
For all data statistical significance between the C. difficile strain VPI 10463 
challenged strain 630-colonized and VPI 10463 challenged naive mice was 
determined by Wilcoxon test.  
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Protection is associated with development of anti-toxin antibody 
responses, but antibody responses are not required for protection. 
Since both strains express nearly identical forms of TcdA and TcdB, we 
questioned if protection might be due to the development of a humoral immune 
response to the toxins (9, 30).  We found that mice previously infected with 630 
developed a high anti-TcdA titer with a median titer of 32,400 (figure 2.4 A, 630 
colonized vs. naïve mice p< 0.01). Using purified toxin, we determined that a 
portion of these antibodies were neutralizing as judged by their capacity to 
prevent TcdA mediated cell rounding (figure 2. 4 B).  We suspect that we were 
unable to detect a neutralizing titer to TcdB due to the fact our total anti-TcdB IgG 
levels were much lower than anti-toxin A IgG (data not shown).  
Since protection was correlated with both pre-colonization and the 
development of an adaptive immune response to the toxins, we next tested if 
adaptive immunity was the sole factor driving protection in our model. To do so, 
we utilized mice defective in recombination-activating gene 1 (RAG), which is 
critical in the development of B and T cells. RAG1-/- mice lack the adaptive arm of 
their immune system (31).  
As observed with wild-type mice RAG1-/- mice, survive infection with strain 
630 and can maintain persistent colonization (figure 2. 5). Following forty days of 
colonization, mice administered a dose of clindamycin via intraperitoneal injection 
and then challenged with the lethal strain VPI 10463.  Strikingly, both the RAG1-/- 
and wild-type (WT) mice pre-colonized with strain 630 were protected following 
the challenge, while the naïve mice of both genotypes succumbed to the infection 
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(figure 2.6 A and B, naïve vs. colonized p<0.05).  Scoring of the colonic 
pathology demonstrated that both the RAG1-/- and WT mice pre-colonized with 
630 had less pathology relative to the naïve mice (figure 2.6 C, naïve vs. 
colonized p<0.05).  These data demonstrate that, in the absence of adaptive 
immunity, pre-colonization with C. difficile is sufficient protect from lethal infection 
with another strain.  Therefore adaptive immune responses are not required for 


















Figure 2.4.  Mice colonized with C. difficile strain 630 develop serum IgG 
response directed against TcdA.  
A.  Titer of serum IgG against TcdA at conclusion of experiment as measured by 
ELISA. Limit of detection was a titer of 400, p = 0.008695. Statistical significance 
was calculated using a Wilcoxon test. 
B.  Neutralizing titer of serum against TcdA or TcdB at conclusion of experiment. 
Limit of detection was a titer of 80 for both toxins. 
 
              
 
Figure 2.5.  RAG1-/- mice can be persistently colonized by C. difficile strain 
630.  
C. difficile strain 630 colonization in infected RAG1-/- and WT mice. Points are the 
median CFU/g feces at a given day, while bars are the upper and lower quartiles. 
The different shapes correspond to mouse genotype, while color corresponds to 





Figure 2.6. RAG1-/- mice pre-colonized with C. difficile are protected from 




Figure 2.6. RAG1-/- mice pre-colonized with C. difficile are protected from 
challenge with a lethal strain of C. difficile  
A. Percent of day of challenge weight at time of necropsy. Figure A shows the 
percent of body weight two days post challenge with the lethal strain relative to 
weight at time of infection.  The dotted line at 100% indicates the value where 
animals neither gained nor lost weight. Both WT and RAG1-/- mice colonized with 
strain 630 and challenged with the highly virulent strain VPI 10463 are protected 
from weight loss where as mice that had no exposure to strain 630 experienced 
significant weight loss, VPI challenged 630 colonized RAG1-/- vs. VPI challenged 
naive RAG1-/- p=0.02016, VPI challenged 630 colonized WT vs. VPI challenged 
naive WT p=0.00021, no statistical difference was detected in comparisons of the 
same treatment between the two genotypes.  Statistical significance was 
calculated using a Wilcoxon test with a Benjamini-Hochberg correction for 
multiple comparisons. Data are from two independently run experiments with 
multiple cages per each treatment group (same mice as in figure 2.5). Each point 
represents a mouse. 
B. Toxin titer from intestinal content of mice in figure 2.6 A as measured by Vero 
cell rounding assay. Both WT and RAG1-/- mice colonized with strain 630 and 
then challenged with VPI 10463 have a lower toxin titer relative to naïve mice 
challenged with VPI 10463, 630 colonized RAG1-/- vs. naive RAG1-/- p=0.04319, 
630 colonized WT vs. naive WT p=0.0007306.Statistical significance was 
calculated using a Wilcoxon test. Limit of detection was 2.3, however for visual 
clarity samples with an undetected toxin titer were plotted below the limit of 
detection. 
C. Histopathology scoring of the colons of mice in figure 2.6 A.  Small panels 
depict scores for each component that makes up the summary score. VPI 
challenged 630 colonized RAG1-/- vs. VPI challenged naive RAG1-/- p=0.0107, 
VPI challenged 630 colonized WT vs. VPI challenged naive WT 
p=0.0003011.Statistical significance was calculated using a Wilcoxon test. 
Protection afforded by low virulence C. difficile strain develops rapidly and 




Protection afforded by the low virulence C. difficile strain develops rapidly 
and depends on exclusion of the lethal strain 
Having ruled out the contribution by adaptive immunity in our model, we 
next sought to determine if protection required treatment with live C. difficile. 
Other groups have demonstrated that triggering of innate immune pathways with 
microbial associate molecular patterns, such TLR5 with flagella, protects against 
acute CDI (32, 33).  Additionally, in other colitis models, both viable and heat-
killed probiotic strains ameliorate disease via stimulation of host pathways (34). 
Thus we tested if defense against severe CDI could be conferred by via pre-
treatment of mice with a high dose of strain 630 heat-killed via autoclave 
treatment. As we had not observed a role for adaptive immunity we shortened 
the model from forty-two days of pre-infection with strain 630 to one day. 
However, since we were additionally testing heat-killed vs. live C. difficile 
colonization we included RAG1-/- mice in this experiment to confirm findings from 
our persistent colonization model.  Susceptible mice were infected with strain 
630, given the equivalent of 109 CFU of heat-killed strain 630, or mock infected.  
Twenty-four hours later mice were all challenged with VPI 10463 (figure 2. 7 A).  
We observed no protective effect due to administration of heat-killed strain 630, 
indicating that protection requires colonization with C. difficile strain 630 not 
merely exposure to antigen (figure 2. 7 B, p<0.05 for all groups indicated).  In this 
short infection model we also verified our finding that adaptive immunity is not 
necessary for protection, as both RAG1-/- and WT mice colonized with strain 630 
were protected after just twenty-four hours of colonization (figure 2. 7 B).  Mice 
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given viable strain 630 were highly colonized with this strain, while mice given 
heat-killed strain 630 or mock were not (figure 2.7 C, p<0.01 for all except WT 
630 pre-colonized vs. mock, p= 0.015).  However total levels of C. difficile (i.e. 
strain VPI 10463 and strain 630) between groups was not significantly different 
(figure 2.7 D, p>0.7).  These data suggest that pre-colonization with strain 630 
limits colonization by the lethal strain.  
Since treatment with viable C. difficile strain 630 was required for 
protection, we examined whether this benefit was mediated through limiting 
levels of the more virulent strain.  Using selective culturing, it is only possible to 
differentiate strain 630 from total C. difficile, as we were unable to identify an 
antibiotic that only strain VPI 10643 was resistant to.  To overcome this limitation, 
we developed a quantitative PCR assay using primers that amplify a target in VPI 
10463 that is absent in strain 630 (figure 2.8 A). Since these primers generated 
nonspecific amplicons when used in the context of the rest of the gut microbiota, 
we used them to follow colonization dynamics of strain VPI 10463 germ-free 
mice.  RAG1-/- germ-free mice were either colonized with strain 630 or left germ-
free; the following day, the germ-free mice in addition to one of the subset of 630-
colonized mice were challenged with VPI 10463. Importantly, using this model 
we determined that the pre-colonization with strain 630 inhibits establishment of 
the lethal strain: we were unable to detect VPI 10463 genomic DNA in the mice 
that were co-infected, despite high overall levels of C. difficile measured by 
quantitative culture (figure 2.8 C, D, E).  In the absence of a microbiota, strain 
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630 provided some protection from severe disease caused by VPI 10463, 
however sample size was too low to detect significance (figure 2.8 B).   
Reports of patients infected with multiple strains of C. difficile suggest that, 
despite our results, infection with multiple strains can occur (35, 36). Thus we 
tested whether the order of colonization altered the ability of one strain to protect 
from challenge with another. We infected susceptible SPF wild type mice with 
strain VPI 10463 and then challenged them with strain 630 the following day, and 
vise versa. When administered as a second inoculum strain 630 was not able to 
rescue the mice from prior infection with the lethal strain (figure 2.9 A).  However 
mice were infected with the two strains simultaneously, both strains were capable 
of colonizing regardless of the relative amount of each administered. While both 
strains were detectable when co-inoculated, protection was not observed unless 
strain 630 was the numerically dominant strain administered (figure 2.9 B).  
Interestingly, when infecting with different ratios of the two strains, the strains 
would not colonize past a threshold of approximately 108 CFU/gram feces, 
suggesting a population carrying capacity for C. difficile in the mouse gut.  
Together these data demonstrate that colonization with high levels of strain 630 





Figure 2.7.  Heat-killed C. difficile strain 630 does not protect mice from 
challenge with lethal strain.   
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Figure 2.7.  Heat-killed C. difficile strain 630 does not protect mice from 
challenge with lethal strain.  
A. Schematic of shortened experimental timeline. 
B. Percent of weight remaining relative to day of challenge in mice pre-treated 
with viable strain 630, heat-killed strain 630 or water (mock). All mice were 
infected with strain VPI 10463 one day following pre-treatment.   Both RAG1-/- or 
WT mice given viable strain 630, did not loose weight following challenge with 
strain VPI 10463, p<0.05 vs. mock or heat-killed 630 treated mice.  There was no 
significant difference between weight-loss in the mock vs. heat-killed 630 
treatments for either genotype. 
C.  Levels of strain 630 in mice at conclusion of experiment.  Levels of strain 630 
were significantly different in mice given viable 630 compared to mice given heat-
treated 630 or mock. RAG1-/-mice given 630 vs. heat-treated 630, p = 0.006 or 
vs. mock, p = 0.006.  WT mice given 630 vs. heat-treated 630, p= 0.008 or vs. 
mock, p= 0.015.  There was no significant difference between colonization in the 
mock vs. heat-killed 630 treatments for either genotype. LOD is 100 CFU/g 
feces; undetected samples were plotted below the LOD for visual clarity. 
D. Total levels of C. difficile colonization in mice at conclusion of experiment. 
There was no significant difference in total C. difficile colonization between any of 
the groups, p>0.7.  
For all figures, squares represent RAG1-/- mice while circles represent wild-type 
(WT) mice. For the data included in each figure, statistical significance was 
calculated using a Wilcoxon test and corrected for multiple comparisons with a 







Figure 2.8.  Pre-colonization with strain 630 excludes colonization by strain 
VPI 10463 in RAG1-/- germ-free mice  
A. Validation of primers for VPI 10463.  Plot of Cq (or crossing-threshold) vs. 
dilution of genomic DNA from VPI 10463, R2 = 0.9929. The resulting PCR 
products formed one melt peak.  
B. Clinical score of mice at time of necropsy.  
C. CFU equivalents of strain VPI 10463 in mice as determined by qPCR using 
primers validated in 2.9 A.  Mice pre-colonized with C. difficile strain 630 have 
undetectable levels of strain VPI 10463 using this assay, LOD is 1.39 X 104 CFU, 
p =0.005741. Samples that did not have amplification are plotted below the LOD 
for visual clarity.  
D. CFU/gram of feces of C. difficile strain 630 across groups as determined by 
selective quantitative culture (630 is erythromycin resistant while VPI 10463 is 
sensitive to the antibiotic). Mice only challenged with VPI 10463 were not 
colonized with strain 630. LOD is 1000 CFU, p = 0.01142. Samples are plotted 
below the LOD for visual clarity. 
E. Total CFU/gram of feces of C. difficile as determined by quantitative culture.  






Figure 2.9.  C. difficile strain 630 cannot rescue mice previously infected 
with strain VPI 10463  
A. Wild-type mice were challenged with either strain 630 or strain VPI 10463, the 
following day mice were given the other strain.  Treatment of mice colonized with 
strain VPI 10463 with strain 630 did not confer protection, n = 5 mice per 
experimental group.  
B.  Mice challenged simultaneously with both strain can be colonized by both 
strains.  Left axis represents Log10 CFU of total C. difficile (closed circle) or 
strain 630 two days post challenge (open circle). Right axis depicts percent of 
baseline weight two days post challenge (triangle). Each different inoculum ratio 
was given to one cage of five mice.  Points represent the median value for each 
treatment while the bars represent the upper and lower quartiles 
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Protection is associated with decreased availability of the amino acid 
glycine, a co-germinant 
Others have reported that pre-colonization with one strain of C. difficile 
provides protection from challenge with a more virulent strain(37-39).  In 
accordance with Freter’s nutrient niche hypothesis, the prevailing hypothesis in 
the field is that consumption of nutrients by the first strain limits the ability of the 
invading strain to grow (37, 40).  We tested this hypothesis in an ex vivo assay 
using sterile filtrates of cecal content from susceptible mice.  Using this approach 
we found that when vegetative C. difficile were inoculated into susceptible mouse 
cecal filtrate, both strains (630 and VPI 10463) displayed significant growth after 
twenty-four hours (figure 2.10 A, p< 0.01).  To test if one day of colonization was 
sufficient to reduce the nutrients required for growth, we tested if vegetative C. 
difficile strain VPI 10463 would grow in sterilized spent culture from one day of 
growth of strain 630.  Spent culture media from twenty-four hour cultures of both 
630 and VPI 10463 supported significant growth (figure 2.10 B).  To test if 
nutrient utilization by strain 630 was different in vivo, we additionally tested 
growth of strain VPI 10463 in cecal filtrate made from mice that were infected 
with strain 630 for twenty-four hours (figure 2.10 C).   This media also supported 
robust growth, demonstrating that in both batch culture and in vivo, twenty-four 
hours of colonization is not sufficient to reduce the nutrients required for growth 
of the invading strain.  Additionally, as vegetative VPI 10463 replicated in the 
spent culture of strain 630, we ruled out the role of inhibition due to secreted 
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products like bacteriocins or even phage in this model.  The lack of inhibiting 
products was confirmed by agar overlay assays (data not shown). 
The primary infectious form of C. difficile is thought to be the 
environmentally stable spore (41).  Recently groups have shown that C. difficile 
colonization can be decreased by reducing germination (42, 43). To date, the 
primary focus of studies evaluating germination of C. difficile spores have been 
on bile acids, specifically the primary bile acid taurocholate (44, 45). In the 
cefoperazone-treated murine model, we previously observed that susceptible 
mice have significantly increased levels of the bile acid taurocholate, a 
compound associated with enhanced germination (46). Since strain 630 cannot 
metabolize taurocholate, we sought other factors that may prevent colonization 
with a second strain (47).   
Other metabolites that are significantly increased in susceptible mice are 
certain amino acids, including glycine (46).  C. difficile can ferment glycine in a 
paired reaction to enhance growth in addition to utilizing this amino acid as a co-
germinant (48-50).  Using an untargeted metabolomics approach, we measured 
the relative levels of the glycine in cecum of conventional mice, which are 
resistant to infection, in addition to levels in the cecum of susceptible and 630 
colonized animals (figure 2.11 A).   Glycine is low in animals that have an intact 
community; however, following treatment with cefoperazone, glycine levels 
increases significantly.  However, less than twenty-four hours of colonization with 
strain 630 significantly reduces glycine in the cecum relative to mock challenged 
susceptible animals.  As we had already ruled out limitation of vegetative growth, 
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we asked if the decrease in glycine in mice colonized with strain 630 altered 
germination of VPI 10463 spores.  For this purpose, we again utilized an ex vivo 
approach using sterile cecal filtrate from mice that had either been off 
cefoperazone for three days (D1 CF) or had been off of cefoperazone for two 
days followed by infection with strain 630 for twenty-four hours (630 D1 CF). PBS 
with both taurocholate and glycine served as a positive control while PBS alone 
and PBS with taurocholate were negative controls. Incubating spores in a given 
condition assessed germination for 15 minutes followed by heat-treatment to kill 
any cells that germinated. When germination occurs, the post-heat CFU is lower 
than the pre-heat amount; if there is minimal germination, the spores survive 
heating and CFU levels should remain constant between the pre and post time 
points. 
Incubation of spores in PBS or PBS + taurocholate had minimal effects on 
the pre and post heat treatment CFU levels. However, heating the spores treated 
with PBS+ taurocholate + 100mM glycine significantly reduced CFU, indicating 
robust germination (figure 2.11B). A similar result was observed in D1 CF 
revealing that it also supports germination.  However, when spores were 
incubated in 630 D1 CF, there was no significant difference in levels of pre and 
post CFU, indicating that 630 D1 CF does not support robust germination.  To 
test whether decreased levels of glycine accounted for the poor germination, we 
attempted to restore germination by adding 100mM glycine to 630 D1 CF. The 
addition of 100mM glycine to 630 D1 CF resulted in germination (figure 2.11B). 
Together these results demonstrate that pre-colonization with 630 reduces levels 
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of glycine in the cecum, which in turn reduces the ability of a second strain to 
















Figure 2.10.  Exclusion of C. difficile strain VPI 10463 by pre-colonization 




Figure 2.10.  Exclusion of C. difficile strain VPI 10463 by pre-colonization 
with C. difficile strain 630 is not mediated by inhibition of vegetative 
growth. 
A. Sterile cecal filtrate from susceptible mice (day 0) was inoculated with 
vegetative cells of C. difficile strain 630, vehicle, or vegetative cells of C. difficile 
strain VPI 10463. Levels of colonization were monitored by quantitative culture at 
time zero and twenty-four hours. Cecal media supports robust growth of both 
strains, p< 0.001.  
B. Filter sterilized spent culture from figure A was inoculated with vegetative 
strain VPI 10463 and colonization was monitored by quantitative culture at time 
zero and six hours. Spent culture media supports robust growth of strain VPI 
10463. Strain VPI 10463 colonization at t =0 vs. t= 6 hours in 630 spent culture, 
p= 0.02622. Strain VPI 10463 colonization at t =0 vs. t= 6 hours in fresh media, 
p= 0.0004095.   Strain VPI 10463 colonization at t =0 vs. t= 6 hours in VPI spent 
culture media, p= 0.0005828.  Data from A and B represent two independent 
experiments using separate batches of cecal media run in at least 
quadruplicates.   
C. Growth of C. difficile strain VPI 10463 in cecal media made from content from 
mice infected for twenty-four hours with C. difficile strain 630.  Strain VPI 10463 
colonization at t =0 vs. t= 24 hours, p= 0.02857.  Statistical significance for all 





Figure 2.11. Colonization with C. difficile strain 630 significantly reduces 
the co-germinant glycine in cecal contents, leading to reduced germination 
of invading strain. 
A. Relative concentration of glycine in cecal content of mice before antibiotics, 
after treatment with cefoperazone and one-day post infection with strain 630. 
Statistical significance for all comparisons was calculated using a Wilcoxon test 
with Benjamini- Hochberg correction.  ** < 0.01  
B. Germination of strain VPI 10463 spores following a fifteen-minute incubation 
in day one cecal filtrate (D1 CF) or cecal filtrates made from mice infected for 
twenty-four hours with strain 630 (630 D1 CF).  PBS supplemented with 0.1% 
sodium taurocholate and 100mM glycine served as a positive control.  Pink dots 
represent both the vegetative and any remaining spores before heating while the 
green dots represent the heat-resistant spores. * < 0.05, ** < 0.01.  Statistical 




The capacity of the gut microbiota to limit colonization by C. difficile has 
been appreciated for over three decades, however the mechanisms of 
colonization resistance remain to be fully elucidated (51-53). Many studies have 
applied on a top down approach to identify and build defined consortia that 
confer the same protection as the intact community (42, 43, 54).  We took an 
alternative approach by building on the observation that administration of a single 
bacterium (non-toxigenic C. difficile) limited colonization (12, 39).  We sought to 
determine how pre-colonization with one strain of C. difficile protects from 
infection by another.  We began by testing the hypothesis that protection was a 
result of both intraspecific bacterial competition and the development of host 
immunity to C. difficile antigen. To do so,  we utilized two well-characterized lab 
strains that despite being differentially virulent in our mouse model express 
nearly identical forms of both TcdA and TcdB (30, 55).  
The multiple infection models, pre-colonization with a less virulent strain is 
sufficient to protect from challenge with a lethal strain of C. difficile, surprisingly 
even in the absence of adaptive immunity. Additionally, protection is dependent 
on high levels of colonization by the less virulent strain and is mediated by 
exclusion of the invading strain. The prevailing theory in the field has been that 
pre-colonization with one strain of C. difficile limits vegetative growth of the 
challenging strain.  Our results challenge this model, as twenty-four hours of 
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growth by one strain is not sufficient to deplete nutrients to levels that limit 
vegetative growth.  
While other bacterial therapies for C. difficile infection such as fecal 
microbial transplants can lead to clearance of C. difficile from the gut (7, 54) C. 
difficile strain 630 was not sufficient to protect mice already colonized with the 
lethal strain. Recently another group reported that a different toxigenic but low 
virulence strain of C. difficile could both protect and treat infection with VPI 10463 
(56). This highlights an important consideration when designing bacterial based 
therapies for treatment of CDI, as unique strains have different relative fitness.   
The major finding from this study is that reduction of glycine following 
colonization with one strain of C. difficile is sufficient to decrease germination of 
the second strain.  This finding provides a novel target for the development of 
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Clostridium difficile, a Gram-positive, anaerobic bacterium is the leading 
single cause of nosocomial infections in the United States. A major risk factor for 
C. difficile infection (CDI) is prior exposure to antibiotics, which increase 
susceptibility to CDI by altering the microbial community enabling colonization. 
The importance of the gut microbiota in providing protection from CDI is 
underscored by the reported 80-90% success rate of fecal microbial transplants 
in treating recurrent infection. Adaptive immunity, specifically humoral immunity, 
is also sufficient to protect from both acute and recurrent CDI. However the role 
of the adaptive immune system in modulating C. difficile colonization has yet to 
be resolved. In this study we sought to determine if adaptive immunity decreases 
C. difficile colonization. Using murine models of CDI, we found that adaptive 
immunity is dispensable for clearance of C. difficile. Furthermore, Random Forest 
analysis of the indigenous untreated microbial community identified community 
profiles that predicted animals that would go on to clear the infection with 76% 
accuracy.  These findings indicate that the indigenous gut microbiota and not 




tract. Adaptive immune response, while able to mitigate acute disease by limiting 
toxin-mediated damage, has no effect on pathogen colonization. This research 
has implications for the design of preclinical studies testing the efficacy of 
vaccines on levels of colonization, as inherent differences in the baseline 
community structure of animals within cages may bias findings. 
 
Introduction 
The anaerobic bacterium Clostridium difficile, is a significant cause of 
morbidity and mortality in the US with an estimated 500,000 cases yearly (1).  A 
major risk factor for C. difficile infection (CDI) is prior exposure to antibiotics (2). 
Antibiotics increase susceptibility to CDI by altering the membership of the 
microbial community and thus the metabolome of the gut, enabling colonization 
(3).  Colonization with C. difficile can manifest in a range of clinical syndromes 
ranging from asymptomatic colonization to inflammatory colitis characterized by 
diarrhea with abdominal pain, and in severe cases death.  In addition to primary 
infection, one in five patients treated for CDI experience recurrent disease (1). 
Disease is mediated by the production of two toxins, TcdA and TcdB, 
which are the major virulence factors for C. difficile (4).  TcdA and TcdB are large 
multi-domain proteins, that inactivate cellular rho-family GTPases via the addition 
of a glucose molecule (5). Inactivation of these key regulatory proteins in 
epithelial cells results in disruption of tight junctions, increased paracellular flow, 




The importance of the gut microbiota in providing protection from CDI is 
underscored by the reported 80-90% success rate of fecal microbial transplants 
in preventing recurrent infection (7-9). Other than microbiome-mediated 
prevention of colonization, adaptive immunity, specifically humoral immunity, also 
provides protection from both acute and recurrent CDI, likely via antibody-
mediated neutralization of C. difficile toxins TcdA and TcdB (10-12). However, 
the role of the adaptive immune system in modulating C. difficile colonization has 
yet to be resolved.  
 In this study we sought to determine if adaptive immunity decreases C. 
difficile colonization. We found that adaptive immunity is dispensable for 
clearance of C. difficile. Instead, the indigenous microbial community 
membership that exists prior to antibiotic administration and infection predicted 
which animals went on to clear the infection. 
 
Experimental Procedures 
Animal Husbandry   
Male and female C57BL/6 specific-pathogen-free (SPF) mice age five to 
twelve weeks were used in these studies.  The wild type mice were from a 
breeding colony at the University of Michigan, originally derived from Jackson 
Laboratories over a decade ago.  The Rag1-/- (B6.129S7-Rag1tm1Mom/J) mice 
were from a breeding colony started with mice from Jackson Laboratories in 
2013. Animals were housed in filter top cages with corncob bedding and nestlet 




cabinet with either sterile water or antibiotic dissolved in sterile water. Mice were 
fed a standard irradiated chow (LabDiet 5LOD) and had access to food and 
water ad libitum.  Cage changes were carried out in a biological safety cabinet.  
The frequency of cage changes varied depending on the experiment. To prevent 
cross-contamination between cages, hydrogen peroxide-based disinfectants in 
addition to frequent glove changes were utilized during all manipulation of the 
animals. The mice were maintained under 12-hours of light/dark cycle in facilities 
maintained at temperature of 72°C +/- 4 degrees.  Animal sample size was not 
determined by a statistical method. Multiple cages of animals for each treatment 
were used to control for possible differences in the microbiota between cages. 
Mice were evaluated daily for signs of disease. Euthanasia was carried out via 
CO2 asphyxiation when mice were determined to be moribund or at the 
conclusion of the experiment. Animal studies were conducted under the approval 
of The University of Michigan Committee on the Care and Use of Animals; 
husbandry was performed in an AAALAC-accredited facility.  
 
Preparation of spores  
Spore stocks of C. difficile strain 630 (ATCC BAA-1382) were prepared as 
previously described with the following modifications; strains were grown 
overnight in 5mL of Columbia broth, which was added to 40mL of Clospore 







In experiments comparing colonization in WT and Rag1-/- mice, age and 
sex matched mice were co-housed for thirty-three days starting at three weeks of 
age and continuing through cefoperazone administration.  Upon infection, 
animals were separated into single genotype housing.  Mice were made 
susceptible to infection by providing ad libitum drinking water with the addition of 
0.5mg/mL cefoperazone (cat # 0219969501, MP Pharmaceuticals) in Gibco 
distilled water. The antibiotic water was changed every two days and was 
provided for 10 days. Following two days of supplying drinking water without 
antibiotic, mice were challenged with either spores or water (mock). C. difficile 
spores suspended in 50µL of Gibco distilled water were administered via oral 
gavage. The number of viable spores in each inoculum was enumerated by 
plating for colony forming units (CFU) per mL-1 on pre-reduced taurocholate 
cycloserine cefoxtin fructose agar (TCCFA). Over the course of the infection, 
mice were weighed routinely and stool was collected for quantitative culture. 
Mice were infected with between 102 and 104 CFU.  
 
Quantitative culture  
Fresh voided fecal pellets were collected from each mouse into a pre-
weighed sterile tube. Following collection, the tubes were reweighed and passed 
into an anaerobic chamber (Coy Laboratories). In the chamber, each sample was 
diluted 1 to 10 (w/v) using pre-reduced sterile PBS and serially diluted. 100uL of 




TCCFA supplemented with either 2 or 6µg/mL of erythromycin.  Strain 630 is 
erythromycin resistant; use of erythromycin in TCCFA plates reduced 
background growth from other bacteria in the sample. Plates were incubated 
anaerobically at 37°C and colonies were enumerated at 18-24 hours. Plates that 
were used to determine if mice were negative for C. difficile were held and 
rechecked at 48 hours.  
 
Splenocytes recovery and transfer 
 Spleens from individual animals were aseptically harvested from donor 
mice. Following harvest, the organ was gently ground up using sterile glass 
slides to remove the cells from the capsule.  Cells were suspended in filter-
sterilized RPMI complete media consisting of RPMI + 1 L-glutamine (Gibco 
11875-093) supplemented with 10% FBS (Gibco 16140-071), 1% 100x Penicillin-
Streptomycin (Gibco 15070-063), 1% 1M HEPES  (Gibco 15630-080), 1% 100x 
non-essential amino acids (Gibco 11140-050), 1% 100mM Sodium Pyruvate  
(Gibco 11360-070) and 0.05mL of 1M 2-Mercaptoethanol (Sigma M3148). The 
cell suspension was passed through 40µm cell strainer to remove large debris. 
Cells were pelleted by centrifugation at 15000 rpm for five minutes at 4°C.  
Following the spin, the pellet was broken up with red blood cells RBC lysing 
buffer (Sigma R7757) and incubated with the solution for no more than five 
minutes. Lysis was stopped with the addition of more RMPI complete media and 
cells were enumerated manually using a haemocytometer. Following 




minutes at 4°C and re-suspended in Leibovitz’s L-15 (Corning 10-045-CV) 
media.  Recipient mice were injected into the peritoneal cavity with 2 x 107 cells 
in 0.25mL L-15 media.  Mice that received vehicle were injected with 0.25mL of 
L-15 media only. 
 
Blood collection 
 Blood was collected from either from the saphenous vein for pre-
treatment time points or via heart puncture at the experimental endpoint.  
Collections from the saphenous veined utilized capillary tubes (Sarstedt 
microvette CB300 Z) while blood collected via heart puncture utilized a polymer 
gel based separator tube (BD Microtainer SST). Following collection, tubes were 
spun according to manufacture’s instructions, serum was aliquoted and stored at  
-80°C until use.  
 
Total IgG ELISA 
 Total serum IgG levels were measured using the IgG (Total) Mouse 
Uncoated ELISA Kit (ThermoFisher Scientific Cat# 88-50400).  Each sample was 
diluted 500-fold in assay buffer and run in duplicate with Southern Biotech TMB 
Stop Solution (Cat# 0412-01) used as the stop solution.  Optical density values 
were measured at 450nm and 570nm on a VersaMax plate reader (Molecular 
Devices, Sunnyvale, CA) and corrected by subtracting the 570nm measurement 
from the 450nm measurement.  A 4-Parameter Standard Curve was used to 





Anti-C. difficile TcdA IgG ELISA 
 Titers of serum IgG specific to C. difficile TcdA (toxin A) was measured by 
ELISA as previously described, with the following modifications (14).   Serum 
from Rag1-/- mice that received an adoptive transfer was diluted 1:50 in blocking 
buffer with subsequent serial dilutions to a final dilution of 1:12150.   Serum from 
the wild-type mice was diluted 1:1200 in blocking buffer with subsequent serial 
dilutions to a final dilution of 1:874800. Each sample was run in duplicate. Each 
plate had the following negative controls: all reagents except serum, all reagents 
except toxin and pre-immune serum if applicable. Additionally, each plate had a 
positive control consisting of toxin coated wells reacted with mouse TcdA 
monoclonal antibody clone TCC8 diluted 1:5000 in blocking buffer (antibodies-
online.com). The optical density at 410nm and 650nm was recorded on a 
VersaMax plate reader (Molecular Devices, Sunnyvale CA).  The absorbance for 
each sample was corrected by subtracting the OD650 reading from the OD410 
reading. The anti-TcdA IgG titer for each sample was defined as the last dilution 
with a corrected OD410 greater than average corrected OD410 of the negative 
control wells plus three times the standard deviation of those wells.  
 
DNA Extraction 
 Genomic DNA was extracted from approximately 200-300 µl of fecal 




now Qiagen) on the Eppendorf EpMotion 5075 automated pipetting system 
according to manufacturer’s instructions.  
 
Sequencing 
 The University of Michigan Microbial Systems Laboratory constructed 
amplicon libraries from extracted DNA as described previously (15).  Briefly, the 
V4 region of the 16S rRNA gene was amplified using barcoded dual index 
primers as describe by Kozich et al. (16). The PCR reaction included the 
following: 5µl of 4µM stock combined primer set, 0.15µl of Accuprime high-fidelity 
Taq with 2µl of 10× Accuprime PCR II buffer (Life Technologies, #12346094), 
11.85µl of PCR-grade water, and 1µl of template. The PCR cycling conditions 
were as follows: 95°C for 2 minutes, 30 cycles of 95°C for 20 seconds, 55°C for 
15 seconds, and 72°C for 5 minutes, and 10 minutes at 72°C. Following 
construction, libraries were normalized and pooled using the SequelPrep 
normalization kit (Life Technologies, #A10510-01).  The concentration of the 
pooled libraries was determined using the Kapa Biosystems library quantification 
kit (KapaBiosystems, #KK4854) while amplicon size was determined using the 
Agilent Bioanalyzer high-sensitivity DNA analysis kit (#5067-4626).  Amplicon 
libraries were sequenced on the Illumina MiSeq platform using the MiSeq 
Reagent 222 kit V2 (#MS-102-2003) (500 total cycles) with modifications for the 
primer set. Illumina’s protocol for library preparation was used for 2 nM libraries, 




raw paired-end reads of the sequences for all samples used in this study can be 
accessed in the Sequence Read Archive under PRJNA388335. 
 
Sequence Curation and Analysis 
Raw sequences were curated using the mothur v.1.39.0 software package 
(17) following the Illumina MiSeq standard operating procedure. Briefly, paired 
end reads were assembled into contigs and aligned to the V4 region using the 
SLIVA 16S rRNA sequence database (release v128) (18), any sequences that 
failed to align were removed; sequences that were flagged as possible chimeras 
by UCHIME were also removed (19).  Sequences were classified with a naïve 
Bayesian classifier (20) using the Ribosomal Database Project (RDP) and 
clustered in to Operational Taxonomic Units (OTUs) using a 97% similarity cutoff 
with the Opticlust clustering algorithm (21).   
The number of sequences in each sample was then rarefied to 10,000 
sequences to minimize bias due to uneven sampling. For feature selection the, 
the shared file was filtered to remove any OTU that was in less than six samples 
across the entire data set. The mothur implementation of LefSe (linear 
discriminant analysis effect size) was used to determine OTUs that differentiated 
IgG positive verses RAG1-/- mice given vehicle nineteen days post transfer (22). 
Following curation in mothur, further data analysis and figure generation was 
carried out in R (v 3.3.3) using standard and loadable packages (23).  The data 





Most of the analysis relied on the R package vegan (24).  This includes, 
determining the axes for the multidimensional scaling (MDS) plots using Bray-
Curtis dissimilarity calculated from sequence abundance. Additionally, vegan was 
used to determine significance between groups using ANOSIM, calculation of 
Inverse Simpson index, and Bray-Curtis dissimilarity between samples.  Final 
figures were modified and arranged in Adobe Illustrator CC.  For the purpose of 
distinguishing between values that were detected at the limit of detection versus 
those that were undetected, all results that were not detected by a given assay 
were plotted at an arbitrary point below the LOD.  However for statistical 
analysis, the value of LOD/√2 was substituted for undetected values.  Wilcoxon 
ranked sum test was used to determine significant differences and, when 
appropriate, reported p-values were corrected for multiple comparisons using the 
Benjamini–Hochberg correction.  
 
Random Forest Analysis 
  Random Forest analysis was performed using R (v.3.2.3) using the 
randomForest package (25, 26). Model parameters ntree and mtry were tuned 
based on the input datasets in order to achieve optimal classification without 
over-fitting (27). Briefly, ntree was calculated by multiplying the total number of 
OTUs included in the analysis by a ratio of the quantity of samples in each 
classification category. Additionally, mtry was defined as the square root of the 
number of OTUs. The informative cutoff for Mean Decease Accuracy (MDA) 




Testing for significant difference in OTU relative abundance following feature 




Reconstitution of adaptive immunity does not impact C. difficile 
colonization  
We sought to determine the contribution of adaptive immunity in clearance 
of C. difficile. To address this question we asked if reconstitution of adaptive 
immunity via transfer of splenocytes from wild-type mice into RAG1-/- mice, which 
are deficient in both B and T cells, is sufficient to clear C. difficile.  Reports of 
immunization with various C. difficile antigen suggests that antibodies to these 
antigens may decrease colonization, so we additionally asked if transfer of cells 
from mice immunized via natural infection with C. difficile might facilitate 
clearance (29, 30).  Splenocytes were collected from wild type mice that were 
either naïve or colonized with C. difficile strain 630 for three weeks (figures 3.1 A, 
3.2 A). The development of humoral immune responses to C. difficile in the donor 
mice was confirmed by the detection of high titers of anti-TcdA IgG in the serum 
while uninfected mice had undetectable levels of anti-TcdA serum IgG  (figure 
3.2 B. p < 0.01).   
To determine the effect of reconstitution of adaptive immunity on C. 
difficile colonization, the recipient mice (RAG1-/-) were colonized with C. difficile 




the recipient RAG1-/- mice two days after C. difficile challenge. Recipient mice 
were randomly assigned to one of three groups that either received splenocytes 
from naïve wild type donors, splenocytes from infected wild type donors, or 
vehicle (figure 3.1 A).  To confirm the successful engraftment of the WT cells, we 
measured total serum IgG in the recipient mice three-weeks post transfer. The 
mice that received splenocytes had significantly higher levels of total serum IgG 
post-transfer compared to the mice that received vehicle (figure 3.2 C, p <0.05). 
Of the mice that received splenocytes, two did not develop any detectable serum 
IgG. There was no difference in the levels of total serum IgG between the mice 
that received splenocytes from infected donors versus uninfected donors (p 
>0.05).   Furthermore, we verified that we successfully transferred anti-C. difficile 
immunity, as anti-TcdA IgG  was detected only in the serum of mice that received 
splenocytes from the infected donors (figure 3.2 D, p < 0.01).   
Following adoptive transfer, levels of C. difficile in the feces were 
monitored for three weeks.  We observed clearance of C. difficile from mice that 
were housed in a single cage.  However, clearance of C. difficile did not occur in 
any of the animals in the two other cages within that same treatment group 
(figure 3.3 A).  Three-weeks post transfer there was no significant difference in 
levels of colonization in any of the groups (figure 3.3 B, p > 0.05).  Notably, in the 
cage that cleared the infection, one mouse had undetectable levels of serum IgG 
while the other three mice in the cage had detectable levels (figure 3.3 C). 
Together these results do not support the model that presence of adaptive 






Figure 3.1. Schematic of the experimental timeline.   
The timeline observed for the mice from which the splenocytes were harvested is 
outlined in Part 1 (donor mice). Splenocytes from the donors were injected into 













Specific OTUs are altered in mice with reconstituted adaptive immunity  
The range in the levels of colonization we observed within each treatment 
group suggested that something other than adaptive immunity might modulate 
levels of C. difficile. The gut microbial community is crucial in protecting from 
initial colonization and for facilitating clearance of C. difficile (31).  We examined 
the gut microbial community structure of the mice over the course of the 
experiment by using 16S rRNA gene amplicon sequencing.  Visualization of the 
Bray-Curtis dissimilarity between the day one post infection communities (before 
the adoptive transfer) using multidimensional scaling revealed that the mice that 
cleared C. difficile had a distinct community compared to the mice that remained 
colonized (figure 3.4, ANOSIM, p = 0.02, R= 0.7363).  This result suggests that 
gut microbiota, rather than the adoptive transfer of splenocytes, enables 
clearance of C. difficile.   
The microbiota and the immune system have been previously shown to 
modulate one another through numerous complex interactions (32, 33). In the 
cefoperazone mouse model of infection, the diversity of microbiota begins to 
recover by two weeks following cessation of the antibiotic (34). Therefore we 
asked if reconstitution of adaptive immunity altered the recovery of the 
community following antibiotics and infection with C. difficile. Our first approach 
sought to determine if we could detect changes in the overall community 
composition of the mice. We calculated the Bray-Curtis dissimilarity between 
each mouse’s day twenty-one sample (nineteen days after the adoptive transfer) 




immunity might prevent the microbiota from returning to the same structure as 
was observed before adoptive transfer. Thus, we investigated whether the mice 
that received splenocytes might have higher Bray-Curtis dissimilarity values 
compared to the vehicle group.  Since we were unable to confirm that we 
successfully restored adaptive immune function in two of mice that received 
splenocytes, we excluded them from the rest of analysis as our questions hinged 
on immune status-gut microbiota interactions (figure 3.3 C). Additionally could 
not calculate this metric for a couple of mice due to the lack of pre-antibiotic 
samples.  Comparing the Bray-Curtis dissimilarity results between the three 
treatment groups revealed no significant differences between any of the groups 
(figure 3.5 A, p> 0.05). We also wondered if addition of adaptive immunity might 
alter alpha-diversity so we calculated the inverse Simpson index of each fecal 
community at day nineteen post transfer (day twenty-one post infection). We did 
not observe any significant differences between the treatment groups by these 
means (figure 3.5 B, p> 0.05). This suggested that by broad metrics of 
community structure, the perturbation of antibiotics and infection with C. difficile 
potentially mask any trends related to reconstitution of adaptive immunity.  
While we saw no significant differences in the recovery of the community 
structure or alpha diversity at day twenty-one post infection, we wondered if 
perhaps the abundance of only a few OTUs were altered by reconstitution of the 
adaptive immune system. For this analysis we grouped all of the mice that 
received splenocytes and developed detectable levels of serum IgG at day 




only received vehicle and thus had undetectable levels of serum IgG were 
designated the IgG negative group. Using sequence abundance from day twenty-
one post infection samples, LefSe identified twenty-seven OTUs with LDA values 
greater than two. The ten OTUs with the highest LDA values were primarily 
enriched in the IgG negative mice (figure 3.6 A).  OTU 3, which is classified as 
Akkermansia, had the highest LDA value. This OTU was found at a significantly 
lower abundance in the IgG positive mice compared to the IgG negative mice. A 
decrease in the abundance of Akkermansia following reconstitution of adaptive 
immunity via adoptive transfer of from wild-type mice into RAG1-/- has been 


















Structure of the fecal microbiota before antibiotics is associated with 
clearance in both WT and RAG1-/- mice.  
To test if the gut microbial community is sufficient to provide clearance of 
C. difficile, we co-housed RAG1-/- mice with WT mice (figure 3.7).  For this 
experiment, we did not perform splenocyte transfer so that the RAG1-/-  mice 
remained without adaptive immunity. After a little over a two weeks of co-
housing, the two groups of mice consisting of both wild-type mice into RAG1-/- 
had significantly different community structures as demonstrated by the MDS plot 
of the Bray-Curtis dissimilarities (figure 3.8 A, ANOSIM, p = 0.046, R= 0.161).   
When the mice were analyzed by genotype rather than by co-housing group we 
found that gut communities of the two genotypes of mice were not significantly 
different  (figure 3.8 B, ANOSIM, p = 0.085, R= 0.1224).  During the infection we 
again observed some mice cleared while others remained colonized. In this 
experiment the two cages of mice that cleared were both from the same 
cohousing group (figure 3.7 and 3.8 C). At the conclusion of the experiment the 
two cages that remained colonized had significantly higher levels of C. difficile 
compared to the mice that cleared (figure 3.8 C, p<0.01).    Cleared or colonized 
mice did not belong to any one genotype but rather to the same co-housing 
group (figure 3.8 C, D). These results in addition to our previous experiment 




















































































































Figure 3.8. Altered microbiota is correlated with clearance in co-housed mice
A.  Multidimensional scaling MDS plot of Bray-Curtis dissimilarity between the fecal microbiota of the 
group A (blue) vs. group B (purple) mice before antibiotic-pretreatment (p=0.046).  Significance was 
determined with ANOSIM in R (v3.2.3) from vegan (v2.4-3). 
B. RAG1-/-  and WT pre-treatment communities are not significantly different when analyzed by geno-
type (same plot as A, clustered by genotype rather than co-housing groups). 
C.  Median temporal C. difficile colonization by cage with interquartile ranges. The colors refer back to  
figure 3.7 and represent co-housing groups prior to infection (p=0.002). 
D.  C. difficile colonization at 40 days post-infection for each cage. The dashed line represents the limit 
of detection.  Undetected results are plotted below the LOD line for visual clarity.  A value equal to the 







Random Forest feature selection identifies OTUs in the pre-antibiotic 
community that differentiates mice that will remain persistently colonized 
vs. clear C. difficile infection.  
Following our previous analyses we made the consistent observation that 
structure of the gut microbiome was associated with clearance of C. difficile, 
even prior to antibiotic treatment (figure 3.8 A). We questioned if specific OTUs 
present in the mice before any intervention that might differentiated mice that 
would go on to clear the infection.  For this analysis, we pooled data from three 
independent experiments (the two described earlier and a third experiment 
including only WT mice) where cages of mice had spontaneously cleared C. 
difficile (figure 3.9 A).  We utilized Random Forest for feature selection to identify 
OTUs that could classify mice as “cleared” or “colonized” based on their pre-
intervention microbiota.  Using the pre-treatment community we could classify 
mice with 76.9% accuracy.  Nine out of the top ten OTUs that most contributed to 
classification were from the Firmicutes phylum (figure 3.9 B and C).  Three OTUs 
in particular (OTUs 52, 93, and 26) ranked highest in their ability to discriminate 
between the groups.  OTUs 52 and 93 were significantly increased in abundance 
in mice that would go on to clear while OTU 26 was enriched in mice that would 
remain persistently colonized.  Therefore we tested if those three OTUs alone 
were sufficient to classify the mice.  Generating a new Random Forest model 
using only those three OTUs, we found that classification improved.  Utilizing the 
median out-of bag error for 100 forest iterations, these three OTUs discriminated 










In this study we tested if adaptive immunity was required for clearance for 
the gastrointestinal pathogen C. difficile.  Results from multiple experimental 
models lead us to conclude that adaptive immunity is dispensable for clearance 
of C. difficile in mice. This finding is in contrast to the paradigm observed in other 
gastrointestinal infections. For example, infection with the attaching-effacing 
pathogen Citrobacter rodentium provides a framework by which adaptive 
immunity plays a role in clearance (36, 37). In addition to the potential direct 
effects, adaptive immunity may have on the bacterium itself, it is known that there 
is a complex interaction loop between the microbiota and host immune response. 
Both the innate and adaptive arms of the immune system regulate membership 
of the gut microbial community while the gut microbiota in turn modulates the 
immune system via the production of metabolites and/or MAMPs (38).  
Our results show that although reconstitution of adaptive immunity can 
alter the abundance of some bacteria in the gut,  it does not impact levels of C. 
difficile colonization.  We found that in the RAG1-/- mice that developed serum 
IgG, there was a decreased abundance of Akkermansia. Another group has also 
observed this result, however we were surprised to see the same trend in our 
model as our mice were also subjected to antibiotic therapy and infection with C. 
difficile. In the two mice that received splenocytes but did not have detectable 




There are numerous reasons why this could be the case, the first being that a 
lack of serum IgG does not preclude successful transfer of T cells which maybe 
responsible for modulating levels of Akkermansia in wild-type mice. Additionally 
fecal IgG or IgA from the mice that had successful transfers may have been 
transmitted via coprophagy in sufficient quantities to modulate the levels of 
Akkermansia in the IgG negative mice that were sharing their cage.  Since the 
relative abundance of OTU3 was not significantly different between the groups in 
the pre-treatment samples we can conclude that the differences we observed 
were a result of the experimental conditions not merely baseline differences in 
their microbiota (figure 3.10 B).  Akkermansia has been implicated in the 
modulation of health processes such as regulation of host metabolism so further 
studies are necessary to fully elucidate the factors that regulate its abundance in 
the gut (39, 40).  
Based on our repeated observations that altered communities early in the 
experimental timeline was associated with clearance of C. difficile we used 
Random Forest to eventually identify just three OTUs that discriminate between 
mice that clear vs. remain colonized with 98% accuracy.  Previous work using a 
similar approach identified OTUs present on the day of challenge that were 
predictive of levels of colonization day one post-infection, however we are the 
first group to assess if the composition of the murine gut microbiota before any 
treatment might affect the outcome of C. difficile infection (41).  Of the three 
OTUs we identified, two belonged to the family Lachnospiraceae and were 




OTU belonged to the Lactobacillus family and was more abundant in mice would 
remain colonized.  Our group has previously observed that high levels of 
Lachnospiraceae is associated with protection from severe disease in a murine 
model of CDI (42).  Furthermore we have also reported that mono-association of 
germ-free mice with a single Lachnospiraceae isolate partially restored 
colonization resistance (43).  It is tempting to speculate multiple Lachnospiraceae 
isolates might be able to fully restore colonization resistance.  However, it 
remains to be seen if the same mechanisms, which prevent initial colonization of 
C. difficile, play a role in clearance of C. difficile.   
Our results suggest that community resilience is intrinsic to the pre-
treatment membership. Additionally these data allude to the possibility of 
predicting those that will be at risk for persistent colonization before antibiotic 
therapy.  However a crucial first step is to determine if predictive OTUs are 
different across perturbations such as various classes of antibiotic therapy. 
Finally, our findings have implications for the design of future preclinical studies 
testing the efficacy of vaccines or other manipulations of adaptive immunity on 
levels of colonization as “cage effects” or inherent differences in the baseline 
community structure of animals within cages may bias findings. Experimental 
approaches that can be implemented to account for the role of microbiota include 
co-housing, using multiple cages for each experimental condition, and the use of 










Figure 3.10. Akkermansia (OTU 3) relative abundance 
A. Relative abundance of OUT 3 in all the mice on day 21-post infection in the 
adoptive transfer experiment. Mice that received splenocytes but did not develop 
detectable total serum IgG have low levels of this OTU unlike the mice that 
received vehicle. There is a significant difference in the abundance of OTU 3 in 
the mice that received vehicle compared to the mice that had successful 
transfers of WT splenocytes P=0.0199 by Wilcoxon test.  
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Clostridium difficile is the leading cause of infectious nosocomial diarrhea. The 
pathogenesis of C. difficile infection (CDI) results from the interactions between 
the pathogen, the intestinal epithelium, host immune system and the 
gastrointestinal microbiota. Previous studies of the host- pathogen interaction in 
CDI have utilized either simple cell monolayers or in vivo models. While much 
has been learned utilizing these approaches, little is known about the direct 
interaction of the bacterium with a complex host epithelium. Here, we asked if 
human intestinal organoids (HIOs), which are derived from pluripotent stem cells 
and demonstrate small intestinal morphology and physiology, could be used to 
study the pathogenesis of the obligate anaerobe C. difficile. Vegetative C. 
difficile, microinjected into the lumen of HIOs, persisted in a viable state for up to 
twelve hours. Upon colonization with C. difficile VPI 10463 the HIO epithelium is 
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markedly disrupted, resulting in loss of paracellular barrier function. Since similar 
effects were not observed when HIOs were colonized with the nontoxigenic C. 
difficile strain F200, we directly tested the role of toxin using TcdA and TcdB 
purified from VPI 10463.  We show that injection of TcdA replicates the disruption 
of the epithelial barrier function and structure observed in HIOs colonized with 
the viable C. difficile.  
 
Introduction 
 Clostridium difficile is an anaerobic, spore-forming bacterium that is the 
leading cause of infectious nosocomial diarrhea and is responsible for over 
14,000 deaths annually (1). Human exposure to C. difficile results in a range of 
manifestations, from asymptomatic colonization, to diarrhea, to lethal toxic 
megacolon. Various models have been used to study C. difficile infection (CDI), 
including in vitro models using transformed cell lines and a variety of in vivo 
models (2-5). In vitro cell culture models are limited in their ability to recapitulate 
complexities of the human gastrointestinal tract, and detailed, real-time study of 
the mucosal epithelium during infection in an animal model is technically 
challenging. 
Human intestinal organoids (HIOs) are three-dimensional spheroids of 
human epithelium generated through directed differentiation of human pluripotent 
stem cells (hPSCs), which include human embryonic stem cells (hESCs) and 
induced pluripotent stem cells (iPSCs). HIOs contain both mesenchymal and 
epithelial tissues that are structurally arranged around a central luminal cavity. 
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The epithelial compartment of the HIO possesses an array of small intestinal cell 
types, including absorptive enterocytes and secretory Paneth, goblet and 
enteroendocrine cells, in addition to Lgr5+ intestinal stem cells (6). HIOs have 
been used to model features of embryonic development, viral infection and 
inflammatory bowel disease(7-9). Due to their similarity to the human 
gastrointestinal tract, HIOs serve as a tractable and physiologically relevant 
model of the human intestine. 
We sought to use HIOs to study the interaction between C. difficile and a 
complex human epithelium. We developed a real-time functional assay to 
demonstrate that HIOs have a robust and effective epithelial barrier, which limits 
paracellular diffusion. In addition, we developed microinjection techniques to 
introduce C. difficile into the lumen of HIOs and found that viable C. difficile 
persists within the HIOs. Colonization of HIOs with C. difficile strain VPI 10463 
results in disruption of the organoid epithelium. These effects were apparently 
dependent on the primary virulence factors of C. difficile, the toxins TcdA and 
TcdB (10) since colonization with a nontoxigenic C. difficile strain did not disrupt 
the HIO epithelium while microinjection of purified TcdA recapitulated the effects 
mediated by toxigenic VPI 10463. These results demonstrate that HIOs can be 
used for detailed molecular and cellular investigation of the pathogenic 
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Human intestinal organoid growth/propagation 
 3-D human intestinal organoids (HIOs) were generated by directed 
differentiation of human pluripotent stem cells (hPSCs) as previously described 
(6, 9, 11). HIOs were generated from the H9 hESC line (WA09, NIH registry # 
0062) and all hESC work described was approved by the University of Michigan 
human pluripotent stem cell oversight committee (hPSCRO). Briefly, hESCs were 
differentiated into endoderm using 100ng/mL ActivinA for three days, and then 
further differentiated into CDX2+ intestinal tissue using 2µM Chir99021 
(Stemgent cat# 04-0004-10)+ 500ng/mL FGF4 for four to six days.  The FGF4 
used to differentiate the intestinal tissue was either obtained from R&D Systems 
(cat# 235-F4) or purified in the lab as previously described (12). During intestinal 
specification, 3D spheroids emerged in the culture dish. Spheroids were 
collected and embedded in Matrigel (BD Bioscience cat# 354234) and expanded 
for 30-60 days in Intestinal Growth Media (IGM) containing Dulbecco's modified 
Eagle medium (DMEM)-F12 medium (12634-010; Gibco by Life 
Technologies) supplemented with L-glutamine, 15mM HEPES, B27 supplement 
(Gibco by Life Technologies cat# 17504-044), penicillin/streptomycin and growth 
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factors containing 100 ng/ml Noggin (R&D Systems cat# 6057-NG), 100ng/ml 
EGF (R&D Systems cat#236-EG) and 5% R-Spondin2 conditioned media (13). 
The media was replaced every 4 days. One- to two-month-old cystic HIOs that 
were > 1mm in diameter were used for experiments. 
 
 Clostridium difficile isolates 
Two strains of C. difficile were used in this study, strain VPI 10463 (ATCC 
43255) a toxigenic strain, which produces both TcdA and TcdB and a 
nontoxigenic clinical isolate F200, described previously (4).  
 
Growth of Clostridium difficile in vitro 
For all experiments, both strains were grown in a vinyl anaerobic chamber 
(Coy Laboratory Products) at 37°C in brain- heart infusion (BHI) broth plus 100 
mg liter-1 L-cysteine. For all microinjection experiments, overnight cultures were 
back-diluted 1:10 and grown for three hours at 37°C. For strain VPI 10463, after 
three hours the culture was further diluted to a starting OD600 of 0.01.  F200 did 
not grow well following a second dilution, so the initial 1:10 back dilution was 
used to start the growth curve for the injections. The OD600 of the cultures was 
measured in the anaerobic chamber using a hand held spectrophotometer 
(Biochrom WPA CO8000 cell density meter, cat# 80-3000-45). After six hours of 
growth from a starting OD of 0.01 the mean OD600 of VPI 10463 used to colonize 
the HIOs was 0.5.  After nine hours from the first 1:10 dilution the mean 
OD600 for F200 used to colonize the HIOs was 0.67. To prepare bacterial 
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supernatants, the cultures described above of either strain VPI 10463 or F200 
were passed through 0.22µm filter to remove the bacterial cells and then FD4 
was added to a final concentration 1mM. 
 
Microinjection of HIOs 
 HIOs were gently removed from the Matrigel in which they were grown by 
cutting around each HIO using a 30-gauge needle.  A cut 1000 microliter pipette 
tip with a large bore that did not mechanically disrupt the HIO was used to 
remove released HIOs from the well and to transfer them to a petri dish. HIOs 
were dividend into experimental groups, and each group of HIOs was re-
embedded into fresh Matrigel in wells of a 24-well tissue culture plate. Thin wall 
glass capillaries (World precision Instruments cat# TW100F-4) were pulled using 
a Narishige PN-30 micropipette puller. The tips of the glass capillaries were cut 
with a scalpel and the capillaries were passed into an anaerobic chamber. In the 
anaerobic chamber, the capillaries were filled with 
either C. difficile+FD4 or filtered supernatant+FD4 using Eppendorf microloader 
tips (Eppendorf, cat# 5242956003). The filled capillaries were then passed out of 
the chamber and loaded on to the microinjector (Sutter Instrument Company, 
XenoWorks Analog Microinjector cat# BRI). FD4 was used in all microinjection 
experiments to aid in visualizing the injections. Even under ambient lighting, the 
green of the FD4 was sufficient for us to ascertain if each injection was 
successful. For example, if a HIO displayed a noticeable outflow of green (FD4) 
immediately following injection, it was excluded from the experiment. Once all the 
 144 
HIOs were injected, the wells were washed twice with DMEM/F12 media (Gibco 
by Life Technologies, cat# 1263-028).  Following the washes, 500µL of IGM with 
growth factors was added to each well and the HIOs were imaged using a 
fluorescent stereomicroscope (Olympus SZX16) at 1x magnification. The HIOs 
were incubated at 37°C in a 5% CO2 humidified incubator.  Images were taken at 
indicated time points post injection. Disruption of barrier integrity was visualized 
by the loss of the FD4 in the lumen of the HIOs. 
 
Clostridium difficile quantitation from HIOs 
For these experiments C. difficile was grown and individual HIOs were 
injected as described above. At 0, 2, and 12 hours post injection each HIO was 
removed with a 1000µL genomic tip (Art by Molecular BioProducts, cat# 2079G) 
and transferred into a sterile 1.7 mL eppendorff tube. The tube was immediately 
passed into an anaerobic chamber. In the chamber, 500µL of anaerobic 1X PBS 
(Gibco by Life Science, cat# 10010-023) was added to each tube and the HIO 
was disrupted using a 1000µL tip. This HIO/PBS mixture was used for 
subsequent dilutions. To determine the level of vegetative C. difficile, samples 
were plated on BHI plus 100 mg liter-1 L-cysteine. Plates were incubated in the 
anaerobic chamber for 24 hours a 37°C at which point colonies were counted.  
 
Vero cell cytotoxicity assay 
The activity of the toxins used in the barrier function assay was 
determined using a cell rounding based cytotoxicity assay.African green monkey 
 145 
kidney (Vero) cells (ATCC CCL-81) were grown to a confluent monolayer in T-75 
Flasks in DMEM (Gibco by Life Technologies cat #11965), supplemented with 
10% heat inactivated fetal bovine serum (Gibco by Life Technologies cat #16140) 
and 1% penicillin-streptomycin (Gibco by Life Technologies cat #15140).  To 
remove the cells from the flask, they were washed with 1X PBS followed by 
treatment with 1mL of 0.25% trypsin. The trypsin was inactivated by the addition 
of 10mL of the supplemented DMEM. The cells were then transferred to a conical 
tube and spun at 1000 rpm for 5 minutes to pellet the cells. For this assay, 1x105 
cells in 90µL of DMEM were seeded in each well of a 96-well plate (Corning cat# 
3596) and incubated for 4 hours. Filtered culture supernatant or purified TcdA or 
TcdB were serially diluted 1:10 in 1X PBS. As a control, the diluted sample was 
then added to an equal volume of either a 1:25 dilution of anti-toxin sera 
(TechLab, cat# T5000) or PBS and incubated at room temperature for one hour. 
Following the incubation, 10µL of the sample was added to the Vero cells and the 
plate was incubated overnight at 37°C in a 5% humidified incubator. The next 
day plates were viewed at 10x magnification for cell rounding. The cytotoxic titer 
was defined as the reciprocal of the highest dilution that produced rounding in 
80% of the cells.  
 
Injection of purified toxins 
HIOs were prepared and injected as described above. For these 
experiments purified C. difficile toxin A (TcdA) or B (TcdB) from strain VPI 10463 
were purchased (List Biological Laboratories cat# 152C or#155D), reconstituted 
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at a concentration of 1µg/µL, aliquoted and stored a -80°C. Due to lot-to-lot 
variation, each new lot was tested for activity using the Vero cell cytotoxicity 
assay. Each HIO was injected with approximately 2µL of either 12.8ng/µL TcdA 
or 25.6ng/µL TcdB with 1mM FD4. For each experiment, new aliquot of toxin was 
thawed and used. 
 
Determining pixel intensity of FD4 in injected HIOs 
To determine pixel intensity of the HIOs ImageJ software was used (14). 
For each well of HIOs a brightfield and fluorescent image was taken. These two 
images of the same well were used to determine pixel intensity. First the 
fluorescent image of the well was opened in ImageJ and converted to 16 bit gray 
scale. Then the brightfield image of the same well was opened in ImageJ and 
synchronized to the gray scale image.  Using the brightfield image, the perimeter 
of the HIO in the well was outlined manually and this region was used to 
determine the mean gray value of the HIO in the fluorescent image. These steps 
were repeated for each HIO in the well for all treatments. The percent pixel 
intensity is defined as the mean gray value of an HIO at a given time point 
divided by the mean gray value of that same HIO at T=0 multiplied by 100. 
 
Basolateral barrier function assay 
Intact HIOs were placed into wells of a 24 well dish containing 500µL IGM 
with growth factors. Purified C. difficile TcdA or TcdB were diluted in IGM. The 
HIOs were incubated in a well containing 400ng/mL of either TcdA or TcdB for 
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two hours at 37°C. After two hours, the HIOs were exposed to 0.1mM FD4 for an 
additional one-hour at 37°C. Negative and positive control HIOs were processed 
in the same manner as toxin-treated HIOs. For positive controls, 2mM EGTA was 
added with the FD4 in the final hour of incubation. Following the incubation, HIOs 
were washed for five to ten minutes with 1X PBS to remove excess FD4. 
Following the wash, HIOs were imaged using a fluorescent stereomicroscope 
(Olympus SZX16). Disruption of barrier integrity was visualized by the presence 
of the FD4 in the lumen of the HIOs. 
 
Immunofluorescence staining and confocal microscopy 
HIOs collected from the barrier function assays were fixed in 4% 
paraformaldehyde (PFA) at room temperature for 15-30 minutes, washed 3 times 
with PBS. HIOs were placed in optimal cutting temperature (O.C.T) compound 
(Sakura, cat# 4583) for 20 minutes, and then placed at -80°C to freeze. Frozen 
sections were cut at 10< µm for immunostaining followed by confocal 
microscopy.  Immunostaining was carried out as previously described (6). 
Antibody information and dilutions can be found in Table 4.1. All 
immunofluorescence images were taken on a Nikon A1 confocal microscope. 
 
Induction of apoptosis with TNFα and IFNγ 
To induce apoptosis, as detected by cleaved caspase 3, HIOs were 
incubated in 1000 ng/mL of TNF (PeproTech cat# AF-300-01A or R&D Systems 
cat# 210-TA-010 note: cytokines from either company were efficient in this 
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assay) plus 1000 ng/mL of IFNγ (PeproTech cat# AF-300-02) for 24 hours. HIOs 
with disrupted barrier function were fixed, embedded, and sectioned as 
described. 
 
Image Processing and Manipulation 
Minimal image processing was used. Image manipulation was limited to 
uniform changes of brightness and/or contrast and to the use of a digital zoom in 
the inset of Figure 4. 3 B. 
 
Statistical Analysis: Statistical analysis was performed using Prism 6 GraphPad 
software. The Mann-Whitney test was used to compare each group to the 
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HIOs have a functional epithelium with an intact paracellular barrier. 
Beyond nutrient absorption, a key function of the gastrointestinal epithelium is as 
a barrier that prevents free passage of antigens from the lumen of the 
gastrointestinal tract to the rest of the body (15). To assess if HIOs possess a 
functional epithelial barrier we microinjected fluorescein isothiocyanate (FITC)- 
dextran with average molecular weight of 4KDa (FD4) into the lumen of HIOs and 
monitored fluorescence over the course of eighteen hours. FD4 is used to 
examine permeability of the epithelial paracellular barrier in a variety of in vitro 
polarized monolayers and in vivo assays (16, 17). In this assay, an intact barrier 
confines the FD4 in the HIO lumen maintaining green fluorescence while loss of 
paracellular barrier integrity results in measureable loss of fluorescence due to 
the diffusion of FD4 out of the lumen.  We observed that FD4-injected HIOs 
maintained fluorescence over the course of eighteen hours (n=5) (figure 4.1 A). 
To quantitate barrier function over time, we measured the fluorescence of 
each HIO throughout the assay and compared the fluorescence at each time 
point to the initial fluorescence at time zero (T=0). The fluorescence of each HIO 
was defined as the pixel intensity per HIO, normalized to the area of each HIO 
(pixel intensity/area). Eighteen hours following injection of FD4, HIOs maintained 
a median of 58.8% of the fluorescence observed at T=0. As a control, we added 
ethylene glycol tetraacetic acid (EGTA, 2mM), a calcium chelator known to 
disrupt tight junctions and adherens junctions to the culture media twelve hours 
 151 
after injecting HIOs (n=5) with FD4. HIOs in the EGTA treatment group 
maintained a median of 90.4% of the fluorescence at twelve hours post FD4 
injection. However, the addition of EGTA at this point resulted in a rapid loss of 
fluorescence such that the median fluorescence of the HIOs at T=18 was 18.3% 
of the intensity at T=0 (figure 4.1 B). By the conclusion of the experiment at 
eighteen hours post FD4 injection there was a statistically significant loss of pixel 
intensity in the EGTA treated HIOs compared to control HIOs. These results 
strongly support the notion that HIOs have a robust paracellular epithelial barrier 
that can be disrupted by chemical means, and also demonstrate that FD4 can be 
used to measure paracellular barrier function over time.  
To confirm these results, we also performed a second “outside-in” barrier 
function experiment (figure 4.2 A). In this experiment, we added FD4 to the tissue 
culture media and reasoned that if the paracellular barrier were disrupted, leak 
would occur from the basal-to-apical (luminal) direction in addition to apical-to-
basal leak demonstrated in figure 4.1. Indeed, when controls HIOs (n=10) were 
incubated in FD4, an intact barrier did not permit FD4 to diffuse into the HIO 
lumen. In contrast, when EGTA was added to the media, 100% of HIOs had a 
disrupted epithelial barrier, and FD4 was observed in the lumen after one hour 
(n=12 individual HIOs) (figure 4.2 B). These results indicate that HIOs have a 
robust paracellular barrier that restricts movement across the epithelium in both 




Figure 4.1 Assessment of HIO epithelial barrier function.   
A. 	Representative images of FD4 dynamics in HIOs following injection. HIOs 
(n=5 per treatment) were injected with FD4 and imaged at 0,2, 10, 12, 14, 16, 
and 18 hours post injection. HIOs retained the majority of injected FD4 within the 
lumen over 18 hours. The addition of EGTA to the media 12 hours after injection 
resulted in rapid loss of FD4 from the lumen indicating loss of epithelial 
paracellular barrier function. Images represent the results from at least three 
independent experiments. 
B. Quantitation of barrier disruption by determination of the fraction of initial FD4 
fluorescence retained or lost over time. Points represent the median and bars 
represent the interquartile range. Eighteen hours after injection control HIOs 
retained significantly more FD4 than the EGTA treated HIOs (p=0.0079, Mann-
Whitney test). 
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Figure 4.2. “Outside-in” barrier function experiment 
To confirm that HIOs had a paracellular barrier function, FD4 was added to the 
media outside of the HIOs.  
A.  Schematic of the barrier function assay. Following treatment, FD4 is added to 
the media containing the HIOs. HIOs with intact epithelium prevent the diffusion 
of FD4 into the lumen where as those with a disrupted epithelium cannot exclude 
FD4.  
B. Brightfield images indicate the location of the HIOs. Untreated HIOs exclude 










Viable C. difficile persists in the lumen of HIOs and damages the 
epithelium.  
To investigate the interaction between C. difficile and human epithelium 
we microinjected C. difficile strain VPI 10463 into the lumen of HIOs. To assess 
the viability of vegetative C. difficile in HIOs, injected organoids were 
mechanically disrupted and cultured under anaerobic conditions. Immediately 
following the injection (T=0), the mean vegetative colony forming units per HIO 
(CFU/HIO) was 2x104 (figure 4.3 A). By T=2 hours post injection the mean 
CFUs/HIO had decreased, as some of the initial inoculum died. Twelve hours 
post injection the mean CFU/HIO was 1x102 suggesting that viable, vegetative C. 
difficile was able to persist within the HIOs for at least twelve hours. 
Histopathologic examination of HIOs twelve hours post injection revealed 
the epithelium was markedly disrupted with sloughing of cells with pyknotic nuclei 
into the lumen (figure 4.3 B). In addition, there were numerous rod shaped 
bacteria in the lumen with what appear to be sub-terminal bacterial spores. 
 Epithelial damage is the hallmark of C. difficile infection in the intestine 
and this is mediated by the virulence factors toxin A and B (TcdA and TcdB). To 
investigate if the epithelial damage observed in HIOs colonized with VPI 10463 
was due to toxin, we microinjected a nontoxigenic C. difficile strain (F200). As 
with VPI 10463, viable F200 persisted within the HIO for 12 hours. However, the 
epithelium of HIOs colonized with F200 appeared intact (figure 4.3 C).  
These results suggest that the VPI 10463 produces toxin in the HIO 
lumen. However, it is known that C. difficile can produce and release toxin into 
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the culture media during in vitro growth. Using the barrier function assay as 
readout of epithelial damage, we determined if the toxigenic strain VPI 10463 
was producing toxin within the HIO. HIOs injected with VPI 10463 lost barrier 
integrity by twelve hours post injection, resulting 22% of the starting fluorescence 
(figure 4. 4 A, B). Importantly, barrier function was maintained in HIOs injected 
with the nontoxigenic F200 isolate of C. difficile. Similar to our previous 
observations (figure 4.1), twelve hours after the injection, the control HIOs (n=5) 
maintained barrier integrity as visualized by the presence of green fluorescence, 
retaining 66% of the initial fluorescence.  As a control for the release toxins into 
culture supernatant during in vitro growth, HIOs were injected with a volume of 
filter sterilized bacterial culture supernatant equal to that used for injection of 
intact bacteria. Filtered supernatant from VPI 10463 or F200 culture media had 
no effect on HIO barrier function (figure 4. 4 A, B). We did, however measure 
detectable cytotoxicity in VPI 10463 supernatant using an in vitro Vero cell 
cytotoxicity assay, suggesting that this strain released toxin into the supernatant, 
but that quantities were not sufficient to disrupt barrier function within the twelve-
hour time frame of our assay (figure 4.5). These results suggest that viable C. 
difficile persists within the lumen of HIOs and that the epithelial damage 












Figure 4.3. Vegetative C. difficile persists in the HIO lumen.  
A. HIOs injected with either C. difficile strain VPI 10463 or F200 were collected at 
0, 2, and 12 h post injection and plated on BHI with cysteine to quantitate the 
number of vegetative CFU per HIO. C. difficile was able to persist in the lumen of 
HIOs for 12 h. Points on the graph represent individual HIOs, and the dashed line 
represents the limit of detection. Bars indicate the means and SEM.  
B. Twelve hours after colonization, HIOs injected with C. difficile were fixed and 
stained using hematoxylin and eosin. The epithelium of the HIO colonized with 
strain VPI 10463 is severely disrupted, and large rods with what appear to be 
subterminal spores are visible (inset) within the HIO (inset is a 3.25× digital zoom 
of the boxed region).  
C. An HIO colonized with the nontoxigenic strain F200 has an intact epithelium 













Figure 4.4. Injection of toxigenic but not nontoxigenic C. difficile results in 
loss of HIO barrier function.  
A. HIOs were injected with FD4 alone (control) (n = 5), a nontoxigenic strain 
(F200) of C. difficile (n = 5), filtered culture supernatant from that strain (n= 6), a 
toxigenic C. difficile strain (VPI 10463) (n = 5), or filtered culture supernatant from 
the toxigenic strain (n = 5). Only VPI 10463-injected HIOs lost barrier function. 
Images are representative of three independent experiments using 5 to 6 HIOs 
per group.  
B. Quantification of epithelial barrier disruption by measuring retention of injected 
FD4 after 12 h. Bars represent the medians and the interquartile ranges. Only the 
HIOs colonized with the toxigenic strain (VPI 10463) lost a significantly greater 
amount of FD4 from the lumen, indicating significant epithelial damage (P = 






















Figure 4.5. Toxin activity of filtered supernatants 
C. difficile culture supernatant was filtered to remove the bacteria and toxin 
activity was assessed using a Vero cell cytotoxicity assay. The culture filtrate 
from strain VPI 10463 had detectable cytotoxicity (black bar), however this level 
was not sufficient to disrupt HIO barrier function when injected into HIOs. Strain 
F200 (the nontoxigenic strain) had no cytotoxicity. The plot is of the mean with 








































Purified C. difficile toxins disrupt HIO paracellular barrier function. 
 
Epithelial damage and loss of barrier function in HIOs injected with C. 
difficile was dependent on the ability of the strain to produce toxin. Since F200 is 
a naturally occurring nontoxigenic strain and not an isogenic mutant of VPI 
10463, we directly determined the effect of TcdA or TcdB purified from VPI10463 
on HIO barrier function. FD4 was combined with purified TcdA or TcdB and the 
mixture was injected into the lumen of HIOs. Compared to controls in which 
100% of HIOs (n=5) retained barrier function, TcdA had a strong effect that 
resulted in a loss of barrier function in 100% of HIOs (n=5) while TcdB had a less 
potent effect on the HIOs and did not appear to robustly disrupt the epithelial 
barrier (n=5) (figure 4.6 A).  Importantly, at the same concentration, TcdA and 
TcdB had similar cytotoxicity on Vero cells in vitro (figure 4.7). When we 
quantitated the relative fluorescence over time, HIOs injected with TcdA lost a 
greater amount of fluorescence compared to HIOs injected with either TcdB or 
FD4 alone  (figure 4.6 B).  
C. difficile toxins are known to inactivate the Rho family GTPases, leading 
to the disruption of cytoskeleton and cellular junctions. To determine if these 
effects were seen in the epithelium of HIOs treated with C. difficile toxins, we 
examined several junctional and cytoskeletal proteins. These include proteins of 
the adherens junctions (AJs) and tight junctions (TJs), which are crucial for the 
maintenance of epithelial barrier function (18). In controls, E-cadherin, a cellular 
transmembrane AJ protein, is localized to the basolateral surfaces of epithelial 
cells and is absent from the apical surface (figure 4.8 A, top panel). In HIOs 
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injected with TcdA, E-cadherin is redistributed and can be seen on the apical 
surface of the epithelium where as in HIOs injected with TcdB, E-cadherin 
localization does not appear to be different from controls (Figure 5A,middle and 
bottom panels). In addition to E-cadherin, we also examined cellular localization 
of Zonula occludens protein 1 (ZO-1) and Occludin (OCLN), both components of 
cellular TJs.  In control HIOs, ZO-1 is present at the TJ near the apical surface of 
the epithelium, whereas OCLN is seen at the TJ and along the lateral surface of 
the cell (figure 4.8 B, top panel). Similar to what was observed with E-cadherin, 
TcdA treated HIOs had dramatic redistributed of tight junction proteins where as 
TcdB treated HIOs were not different from controls (figure 4.8 B, middle and 
bottom panels). Reports by others have demonstrated that OCLN is internalized 
via endocytosis upon disruption of the TJ, and can be visualized in endocytic 
vesicles. We did not observe obvious enodcytic vesicles containing OCLN, 
however, this is likely due to differences in tissue processing conditions that are 
required to visualize vesicles (19). Lastly, we used Phalloidin staining to assess 
the organization of F-actin, and acetylated alpha tubulin (AcTub) 
immunofluorescence to visualize stabilized microtubules within the cell (figure 4. 
8 C). In controls, F-actin was strongly localized to the apical surface of the 
epithelium and weak staining was seen along the lateral and basal surface of the 
epithelium (figure 4.8 C top panel). Similarly, AcTub staining was strongest on 
the apical side of the cell, but was also weakly present throughout the cell and on 
the basal surface (figure 4.8 C, top panel). Compared to FD4 injected controls, 
HIOs treated with TcdA had a marked reduction of F-actin with areas where 
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staining was undetectable. In addition, HIOs treated with TcdA displayed a 
severe disruption of AcTub at the apical border of the epithelial cells (figure 4.8, 
middle panel), consistent with previous reports (20). In contrast, TcdB treated 
HIOs showed F-actin distribution and apical AcTub staining that was similar to 
controls, whereas AcTub immunofluorescence on the basal side of the cells 
appeared to be disrupted, indicating that TcdB had a mild effect on the basal side 
of the HIO epithelium (figure 4.8 C, bottom panel). In conclusion, examination of 
the cellular effects of purified C. difficile toxin on HIO epithelium demonstrated 




















Figure 4.6 Purified TcdA and TcdB injected into the lumen of HIOs disrupt 
paracellular barrier function.  
A. Representative images of FD4 leakage from the lumen of HIOs treated with C. 
difficile toxin. HIOs (n = 5 per treatment) were injected with FD4 alone (top), with 
purified TcdA (middle), or with TcdB (bottom). In this system, TcdA is more 
potent than TcdB. Images are representative of at least three independent 
experiments using 5 to 6 HIOs per group.  
B. Quantitation of fluorescence of each HIO relative to time zero. Injection of 
purified TcdA into HIOs causes significantly greater loss of paracellular barrier 
function than injection with either TcdB (blue asterisk, P = 0.0159) or FD4 alone 
(red asterisks, P = 0.0079). Points represent the median percentages, and bars 
represent the interquartile ranges. The data were analyzed using the Mann-
Whitney test. Control data presented in panels A and B are the same as those 







Figure 4.7. Toxin activity of purified TcdA and TcdB used in injections.  
Purified toxin was tested in cell cytotoxicity assay. At the same 




Figure 4.8. Cellular effects of injection of HIOs with TcdA or TcdB 
HIOs were injected with FD4 alone (control), TcdA, or TcdB and monitored for 
disruption of barrier function. At 18 h postinjection, the HIOs were fixed and 
stained.  
A. The normal basolateral distribution of the adherens junction protein E-
cadherin (ECAD) is disrupted following injection of TcdA. In these HIOs, ECAD is 
redistributed and can be seen on the apical surface of the epithelium. HIOs 
injected with TcdB maintain a basolateral distribution of ECAD similar to that of 
the controls.  
B. Altered localization of TJ proteins ZO-1 and OCLN following injection with 
TcdA. In control HIOs, ZO-1 is present at the apical surface of the epithelium, 
whereas OCLN is seen at the lateral surface of the cell. In HIOs injected with 
TcdA, apical ZO-1 at TJs is lost and OCLN no longer is restricted to the lateral 
surface, while TcdB-injected HIOs have ZO-1 and OCLN immunofluorescence 
similar to those of the control. DAPI, 4′,6-diamidino-2-phenylindole.  
C. HIOs were stained with phalloidin to assess the organization of F-actin and 
acetylated alpha tubulin (AcTub) to visualize stabilized microtubules. In control 
HIOs, F-actin is strongly localized to the apical surface of the epithelium, while 
AcTub immunofluorescence is strongest on the apical and basal sides of the cell. 
Compared to control HIOs injected with TcdA, epithelial cells displayed a 
reduction of F-actin staining, with areas where staining was undetectable, and 
showed a severe disruption of AcTub at the apical border. In contrast, in HIOs 
injected with TcdB, phalloidin staining was similar to that of the controls and 
AcTub immunofluorescence was mostly similar to that of the controls, with a mild 




Basolateral addition of purified toxins disrupts HIO barrier function.  
Studies have suggested that TcdA acts to disrupt the localization of tight 
junction proteins, which then allows for TcdB to act on the basolateral side of the 
cell (21). Moreover, a “fence and gate” model has recently been proposed 
whereby C. difficile toxins cause a redistribution of basal-lateral proteins to the 
apical surface so that the bacteria can bind to the cell surface (2). However, the 
receptors for TcdA and TcdB have not been definitively identified, and it has not 
been conclusively shown that toxins preferentially affect the apical versus basal 
surfaces of the epithelium. Therefore, to test a differential effect of apical (Figure 
5) versus basal exposure to toxin, we added FD4 along with TcdA or TcdB to the 
tissue culture media in order to expose HIOs to toxin on the basal side of the 
epithelium (figure 4.9). In this experiment, since FD4 was added outside the HIO, 
inward leak and fluorescence inside the HIO lumen indicates a disrupted 
epithelial barrier. Consistent with apical exposure (figure 4.8), and compared 
controls, TcdA was again more potent than TcdB at disrupting barrier function 
(figure 4.9).  While barrier function remained intact in 100% of control HIOs 
(n=10), TcdA disrupted barrier function in 100% of HIOs (n=13) and the barrier 
was disrupted in only 23% of TcdB treated HIOs (n=22). Importantly, barrier 
disruption in toxin treated HIOs was not due to apoptosis (figure 4.10). Taken 
together, these results indicate that the C. difficile toxins TcdA and TcdB have 
the ability to interact with both the apical and basolateral aspects of the 




Figure 4. 9 Basolateral exposure to purified toxins causes loss of barrier 
function. 
Purified TcdA or TcdB was added to tissue culture media containing HIOs, 
followed by the addition of FD4. In this assay, the loss of paracellular barrier 
function was indicated by diffusion of FD4 into the lumen of HIOs, while HIOs 
with an intact epithelium excluded FD4. Bright-field images show the location of 
the HIOs. Images taken under fluorescent light indicate barrier function status. 
None (0/10) of the untreated HIOs lost barrier function, whereas 100% (13/13) of 
HIOs treated with TcdA lost barrier function, while only 23% of HIOs treated with 








Figure 4.10 Loss of barrier function following treatment with TcdA or TcdB 
is not due to caspase-3 mediated apoptosis.  
Controls, EGTA treated, and 400ng/ml of TcdA or TcdB treated HIO were stained 
for cleaved caspase-3 an indicator of apoptotic cell death. Treatment with the 
cytokines TNFalpha and INF-gamma induces massive cell death and serves as a 




The pathogenesis of CDI is multifaceted and involves interactions 
between the host, the gut microbiota and C. difficile (22-24). In order to study the 
effect of C. difficile colonization on human epithelium, we developed techniques 
to colonize the HIO lumen with viable vegetative C. difficile. The vegetative cell is 
sensitive to oxygen leading to the concept that the environmentally stable spore 
is responsible for transmission (25). Our data suggests that the vegetative cell 
can be tolerant of oxygen in the lumen of HIOs as viable C. difficile persists 
despite cultivating the HIOs in ambient oxygen conditions. While it may be 
surprising that C. difficile can persist in HIOs grown at ambient oxygen levels, 
many anaerobes can tolerate oxygen under conditions that limit toxicity of 
reactive oxygen species (26, 27). Preliminary measurements using an oxygen 
micosensor indicate that the lumen of HIOs has lower than ambient   oxygen 
levels, with the luminal oxygen concentrations ranging from 5-15% (data not 
shown).  A recent report suggests that some strains of C. difficile may be able to 
grow even at these high levels of oxygen (28).  
Recently, others have utilized mouse-derived enteroids (epithelium-only 
organoids) to study host-microbe interactions (29, 30). A key difference between 
those reports and the data presented here is that our system utilizes organoids 
derived from human cells rather than mouse intestinal crypts. In addition, this is 
the first report demonstrating that organoids can be colonized with an obligate 
anaerobe.  
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A caveat of our model is that while HIOs are more similar to the human 
small intestine, CDI manifests clinically as colitis. However, the small intestinal 
epithelium is relevant to study C. difficile pathogenesis as patients with ileal 
pouch anal anastomoses will develop clinical CDI. Additionally, animal ileal loop 
models have historically been used to understand the pathogenesis of this 
infection with respect to the activity of the toxins on the host.  
Many previous studies of C. difficile virulence and pathogenesis have 
focused on the glucosyltransferase toxins TcdA and TcdB. Depending on which 
system has been used to study these toxins, the relative activities of TcdA   and 
TcdB differ. Previous studies in cell culture lines demonstrate that TcdB has 
greater cytotoxicity than TcdA (31, 32). However, TcdA has been reported to be 
more potent than TcdB in animal models, which recapitulate the diverse cell 
types and structure of the gastrointestinal tract (33, 34). The greater activity of 
TcdA in the organoid may reflect the fact that the organoid epithelium responds 
more like the intestinal epithelium in situ instead of like in vitro-cultured cell lines. 
One caveat to consider in light of our observations is the growth conditions for 
the HIOs, which includes media containing EGF, Noggin and R-Spondin2. 
Previous studies have shown the EGF can reduce TcdA and TcdB induced 
damage in the colonic mucosa (35). Thus, it is possible that EGF present in the 
media is able to attenuate the effect of one toxin (TcdB) more than another 
(TcdA), a possibility that will be tested in the future. However, our finding that 
TcdA caused greater disruption of HIO epithelial barrier function than TcdB is 
consistent with the finding that TcdA (but not TcdB) can inactivate the Ras family 
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GTPase Rap, which regulates cell-cell junctions (36). Our FD4-based assay 
measures disruption of intercellular junctions, which allows paracellular leak, and 
is consistent with the described activity of TcdA. Finally our results showing that 
TcdA can disrupt barrier function when added apically and both TcdA and TcdB 
can disrupt barrier function when exposed to the basolateral surface demonstrate 
that toxins can interact with receptors on both surfaces. As yet, the definitive 
receptor for either of these toxins is not known, however, basolateral activity of 
toxins have been previously reported, and so it is possible that receptors exist on 
both apical and basolateral cell surfaces (37). The HIO system may represent a 
new avenue to search for this important molecular target. 
The gastrointestinal epithelium is an interface between the host and 
the environment and is crucial for many aspects of health including nutrient 
absorption, maintenance of immune homeostasis as well as a selective barrier 
against antigens (38, 39). Defects in intestinal epithelial barrier function have 
been associated with the pathogenesis of inflammatory bowel diseases, celiac 
disease and enteric infections (40). Herein, we demonstrated that HIOs have an 
intact polarized epithelium with paracellular barrier function, which can be used 
for detailed, real-time studies of both normal physiological barrier function as well 
as barrier dysfunction in the context of chemical perturbations or infection. As 
such, this system represents the first robust three-dimensional, non-transformed, 
primary human intestinal system to study the effects of C. difficile Infection and 
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The work outlined in the preceding chapters tested the central hypothesis 
that protection from C. difficile disease reflects the combined effects of host 
immunity and bacteria/bacteria competition. The major findings from this work 
are: 1) in a murine model, colonization-resistance to a lethal C. difficile infection 
can be restored by pre-colonization with a single bacterium, specifically a less 
virulent strain of C. difficile; 2) pre-colonization with the less virulent strain results 
in decreased levels of amino acids, such as glycine, which serve as spore co-
germinant; 3) pre-colonization leads to decreased germination of the lethal strain, 
likely due to decreased availability of amino acid co-germinant. Surprisingly, 
while numerous studies have demonstrated that adaptive immunity is sufficient to 
protect from CDI (1-4), in the context of our experimental conditions, it was not 
required for either protection from acute disease when mice were pre-colonized 
with C. difficile strain 630 or for clearance of C. difficile. This chapter includes a 
summary of the main findings from each of the previous chapters in addition to 




Exploring How Intraspecific Interactions Prevent Colonization by a Lethal 
Strain of C. difficile 
 
In chapter two, I developed a model of subclinical C. difficile infection and 
showed that colonization with one strain of C. difficile prevents infection by a 
highly virulent strain. Using mice deficient in both B and T cells as well as mice 
that lack a microbiota, I demonstrate that protection is independent of adaptive 
immunity and occurs via exclusion of the highly virulent strain.  
Others had previously observed that colonization with one strain of C. 
difficile protects from challenge by a second strain (5-7). Borriello et al. 
suggested that prior colonization with a non-pathogenic strain limited colonization 
by a second strain by filling C. difficile’s preferred spatial niche in the gut (6, 8). In 
support of this hypothesis the proteinaceous surface layer of C. difficile, termed 
S-layer protein A (SlpA), was shown to bind to the intestinal epithelium (9). 
Furthermore, pretreatment of cells with purified SlpA from one strain significantly 
decreased adherence of another strain in vitro (10).  Together these data led me 
to hypothesize that SlpA mediated adherence to the epithelium by C. difficile 
might contribute to the protection by preventing colonization of the invading 
strain.  
I sought to test this hypothesis in vivo by treating susceptible mice with 
SlpA from C. difficile strain 630.  I reasoned that SlpA might competitively inhibit 
adherence of the invading strain thereby limiting its colonization.  To test this, I 
partially purified SlpA from overnight cultures of C. difficile strain 630 using a low 
pH glycine buffer as previously described (10, 11). While SlpA is expressed as a 
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single precursor-peptide, it is cleaved into two smaller peptides termed the low 
molecular weight (LMW) and high molecular weight (HMW) subunits. Both the 
LMW and HMW subunits of SlpA were clearly visible on a commasie stained gel 
after partial purification (figure 5.1).  
Mice were made susceptible to CDI by administration of 0.5mg/mL of the 
antibiotic cefoperazone. Following 2 days off of the antibiotic, 100uL of 3mg/mL 
SlpA prep or 100uL of PBS was given to mice via orogastric administration 3 
hours before infection and every 3 hours thereafter for a total of 5 treatments. 
Mice treated with PBS (mock) and one of the SlpA treated groups of mice were 
challenged with C. difficile strain VPI 10463. A third group of SlpA treated mice 
remained unchallenged to monitor the effect of SlpA alone.  
Following pretreatment with SlpA, we did not detect a difference in levels 
of colonization of C. difficile strain VPI 10463 compared to mock treated animals 
(figure 5.2 B) Furthermore, all mice that were challenged with of C. difficile strain 
VPI 10463 developed signs of disease; overall there was no significant difference 
between the SlpA and mock-treated mice (figure 5.3 A,C).  
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Figure 5.1 Commassie stained 10% Bis-Tris gel of preparations of C. 
difficile strain 630.  
Lane numbers are labeled across the top of the gel. Lanes 1 is the protein 
standard, molecular weights are labeled on the far left side of the gel. Lanes 2,3 
show SlpA partially purified by low pH glycine extraction. In lane 3, the grey 




               
Figure 5.2 Administration of partially purified SlpA from C. difficile strain 
630 does not protect mice from challenge with the lethal strain 
A. Change in mouse body weight from day of infection to necropsy.  Mice treated 
with SlpA only lost a small amount of weight (green). Mice treated with SlpA and 
then challenged with C. difficile strain VPI 10463 (blue) lost the same amount of 
weight as mice that were only infected with C. difficile strain VPI 10463 (red).  
B. C. difficile strain VPI 10463 CFU in the feces twenty-four hours after infection. 
There was no difference in colonization between the mice treated with SlpA 
(blue) compared to untreated mice (red).  
C. Clinical score of mice at time of necropsy. Mice only given SlpA had minimal 
signs of disease (green).  Both the mice treated with SlpA (blue) and untreated 

































































Together these data suggest that SlpA may not be the main driver of 
protection in vivo.  However a major limitation of this experiment was that we had 
no method to confirm that the amount of SlpA given was sufficient to mimic 
colonization with C. difficile strain 630. An alternative tactic would be to challenge 
mice with C. difficile strain 630 deficient in SlpA and ask if this isolate no longer 
provides protection from challenge with VPI 10463.  We did not pursue this 
approach as reports in the literature claim that slpA is an essential gene.  
 If this hypothesis were to be pursued in the future three things should be 
determined first: 1) C. difficile adheres to the gut epithelium in vivo, 2) pre-
colonization with C. difficile strain 630 blocks adherence of strain VPI 10463, 3) 
SlpA mediates C. difficile adherence to mouse epithelium in vivo.  While the data 
presented by no means rule out the role of SlpA in limiting colonization of C. 
difficile, they do not support it either.  
In chapter two, we showed that pre-colonization decreases levels of the 
amino acid glycine, a co-germinant for C. difficile spores, leading to decreased 
germination of the lethal strain. These results provide a novel metabolite to target 
for restoration of colonization resistance to C. difficile. C. difficile, in addition to 
many other Clostridium species can ferment amino acid pairs, including glycine,  
in processes called Stickland reactions (12-14).  Since glycine is both a signal for 
germination as well as a potential nutrient source for vegetative growth of C. 
difficile (15, 16), it is tempting to speculate that glycine is a preferred nutrient 
source for C. difficile.  Interestingly SlpA was shown to bind human collagen I (9), 
which is rich in the amino acids proline and glycine. It is possible that following 
	 184 
toxin mediated disruption of the gut epithelium; SlpA facilitates colonization by 
binding to collagen, which might serve as a food source for the vegetative cell.  If 
this were true, then SlpA may be more important for persistence of C. difficile 
rather than initial colonization.  
While I utilized a virulent but low pathogenic strain of C. difficile in these 
studies due to its genetic tractability, in the clinic, non-toxigenic strains of C. 
difficile have been used to protect patients from disease (17).  However, it is 
worrying that there have been reports of transfer of the toxin genes from a 
toxigenic strain into a non-toxigenic strain in vitro (18, 19).  This suggests that 
ultimately non-toxigenic C. difficile may not the best therapy for CDI. It is likely 
that next generation probiotics will contain defined consortia of strains that confer 
colonization resistance and/or protect from toxin (20). Future work should focus 
on confirming the role of glycine in limiting colonization of C. difficile as well 
explore the use of other species capable of removing glycine from the gut as an 
alterative means to restore colonization resistance to C. difficile.   
 
Exploring the Contribution of Adaptive Immunity in Clearance of C. difficile 
In chapter three, using the murine model developed in chapter two, we 
show that adaptive immunity is also not required for clearance of C. difficile from 
the murine gut. While restoration of humoral immunity did result in changes in the 
abundance of some members of the microbiota it was not required for clearance 
of C. difficile. Furthermore, combining data from multiple experiments we found 
that three OTUs present in the indigenous pre-treatment community could 
classify mice that would go on to clear with over 90% accuracy. This finding is 
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important because it highlights the role of bacterial factors independent of 
adaptive immunity in modulating colonization of C. difficile.  Furthermore, while 
those three OTUs were differential abundant before antibiotics they were not very 
abundant at the time of infection (data not shown). This raises the question of 
whether those OTUs directly inhibit C. difficile or if they are just biomarkers of a 
more resilient gut microbial community.  
The most important finding from this study is that differences in the 
microbiota before the start a treatment may greatly impact the outcome of 
experiments. Moving forward preclinical studies should strive to use multiple 
cages of animals to minimize bias due to the variation of the gut microbiota of 
animals.   
 
Summary and implications of chapter four 
 
In chapter four I describe the use of human intestinal organoids as a 
model for studying both C. difficile persistence and toxin mediated epithelial 
damage.  While the high oxygen levels in HIOs makes them imperfect models to 
study colonization, they are ideal for studying the cellular effects of the toxins on 
a complex epithelium. While the work in chapters two and three demonstrate that 
limiting colonization can prevent CDI, protection can also be mediated by 
modulation of toxin production and activity. Thus it is important to continue to 
study the factors that modulate toxin-mediated damage to the host epithelium. At 
the time of publication, we did not know that one TcdB receptor belongs to the 
Wnt receptor frizzled family of proteins (21). It would be in interesting and 
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informative to explore if different organoids culture conditions alters the observed 
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